pompeepee的个人主页 - 老虎社区

pompeepee

暂无个人介绍

IP属地：未知

132关注

6粉丝

0主题

0勋章

2021-09-19

oof

FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations

2021-08-24

whee

抱歉，原内容已删除

2021-08-18

wa

3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over Fist

2021-08-11

wow

抱歉，原内容已删除

2021-08-09

likee

抱歉，原内容已删除

2021-08-08

yay

抱歉，原内容已删除

2021-08-06

yay

DraftKings EPS misses by $0.18, beats on revenue, boosts full year revenue guidance

2021-08-03

wah

August is among the worst months of year for the stock market. Here's how to play it.

2021-08-03

wah

August is among the worst months of year for the stock market. Here's how to play it.

2021-08-02

wowew

Commodities Week Ahead: Oil, Gold Eye U.S. Jobs Report As China PMI Slides

2021-07-30

wow

Facebook Metaverse, Next Wave Of Growth Opportunities

2021-07-30

like

Amazon Reports Earnings Thursday. Expect a Blowout.

2021-07-28

commenting

抱歉，原内容已删除

2021-07-26

likee

抱歉，原内容已删除

2021-07-24

wow

抱歉，原内容已删除

2021-07-23

eow

Wall Street ekes out gains, led by tech, growth stocks

2021-07-22

yes

抱歉，原内容已删除

2021-07-22

weweew

Cryptocurrency-related stocks soar in premarket trading

2021-07-21

wow like

Chembio Shares Double on $28 Million COVID Diagnostic Test Order

2021-07-19

likey

Investors are very scared even with stocks near record highs

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3577522329316309","uuid":"3577522329316309","gmtCreate":1614485183793,"gmtModify":1614485183793,"name":"pompeepee","pinyin":"pompeepee","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":132,"tweetSize":35,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.45%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":887349558,"gmtCreate":1631982686474,"gmtModify":1632804968350,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"oof","listText":"oof","text":"oof","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/887349558","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","kind":"news","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834592172,"gmtCreate":1629812270596,"gmtModify":1631889859995,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"whee","listText":"whee","text":"whee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/834592172","repostId":"1154386229","repostType":4,"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831136474,"gmtCreate":1629294304098,"gmtModify":1631889860035,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"wa","listText":"wa","text":"wa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/831136474","repostId":"2160735178","repostType":4,"repost":{"id":"2160735178","kind":"highlight","pubTimestamp":1629292500,"share":"https://www.laohu8.com/m/news/2160735178?lang=&edition=full","pubTime":"2021-08-18 21:15","market":"us","language":"en","title":"3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2160735178","media":"Motley Fool","summary":"Berkshire Hathaway's stakes in these top-tier companies were reduced during the second quarter.","content":"<p>When it comes to investing prowess, Warren Buffett is in a class of his own. Since taking the helm of conglomerate <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in 1965, he's helped deliver an average annual return to shareholders of 20%. That's 56 years and an <i>average annual return of 20% </i>over those 56 years! Taking into account the year-to-date gain from the Class A shares (BRK.A), Buffett has overseen a nearly 3,400,000% return in Berkshire Hathaway's stock while CEO.</p>\n<p>Suffice it to say, when Warren Buffett buys, adds to, reduces, or sells out of a stock, Wall Street and the investing community pay very close attention. On Monday, Aug. 16, investors received their latest peek under the hood.</p>\n<p><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</p>\n<h3>Berkshire Hathaway was a net-seller of stocks in Q2</h3>\n<p>Companies and individuals managing at least $100 million in assets are required to file Form 13F with the Securities and Exchange Commission 45 days after a quarter has ended. A 13F provides a (dated) snapshot of what institutional investors, hedge funds, or market mavens were holding as of the end of the most recent quarter (June 30).</p>\n<p>Berkshire Hathaway's latest 13F showed a considerable amount of selling, rather than buying. In total, four stocks were purchased or added to during the second quarter, with the biggest buy being grocery chain <b>Kroger</b>. More than 10.7 million shares were added, boosting Berkshire Hathaway's stake to almost 61.8 million shares.</p>\n<p>On the other hand, 11 stocks were reduced or completely given the heave-ho. <b>Axalta Coating Systems</b>, Berkshire Hathaway's only exposure to the materials sector, was completely sold. Additionally, the Oracle of Omaha and his investing team sent <b>Biogen</b>&nbsp;and <b><a href=\"https://laohu8.com/S/LFG.AU\">Liberty</a> Global </b>(Class A, LBTYA) packing. Note, Berkshire still owns a reduced stake in <b>Liberty Global</b>'s Class C shares (LBTYK).</p>\n<p>But among the eight other holdings that were reduced are three stocks that investors should be buying hand over fist. Buffett and his investing lieutenants may have an impressive track record, but they're not infallible.</p>\n<p><img src=\"https://static.tigerbbs.com/fe7d1b8c040ec63440ca65517ac114c2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The all-electric 2022 Chevrolet Bolt EUV. Image source: General Motors.</p>\n<h3>General Motors</h3>\n<p>First up is auto stock <b>General Motors</b> (NYSE:GM), which has been consistently trimmed in recent quarters. During the second quarter, Buffett and his team reduced Berkshire's GM stake by 7 million shares, leaving the company with 60 million shares.</p>\n<p>Why reduce the General Motors stake? One possibility is persistent supply chain disruption caused by the coronavirus pandemic. Chip shortages have caused automakers to halt or reduce production of certain models, which should adversely affect their operating performance in the near term.</p>\n<p>Another possible reason Buffett or his investing lieutenants, Todd Combs and Ted Weschler, may have chosen to lighten the load is GM's valuation. Since emerging from bankruptcy over a decade ago, GM's market cap was never higher than it was during the second quarter (a peak of $92 billion).</p>\n<p>But whatever the reasoning is, selling shares of General Motors isn't a smart move. If anything, General Motors is more attractive now than it's been in over a decade. That's because it's going to benefit from a multi-decade vehicle replacement cycle as consumers and enterprises go electric.</p>\n<p>In mid-June, General Motors announced its plans to up spending on electric vehicles (EV), autonomous vehicles, and battery technology to $35 billion through 2025. That's a 75% increase from its previous spending commitment on clean-energy solutions from prior to the pandemic. The expectation is that GM will launch 30 new EVs worldwide by mid-decade.</p>\n<p>General Motors also has significant inroads in China, the world's largest auto market. With a number of established brands in the Chinese market and the infrastructure necessary to ramp up production, GM shouldn't have any issue gobbling up EV market share.</p>\n<p>Currently valued at less than 8 times Wall Street's earnings-per-share forecast for 2022, GM is a screaming buy.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F639553%2Fusb-mobile-app.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: U.S. Bank (U.S. Bancorp is U.S. Bank's parent company).</p>\n<h3>U.S. Bancorp</h3>\n<p>Another surefire winner that was, once again, reduced very modestly by Buffett and his team during the quarter is regional bank stock <b>U.S. Bancorp</b> (NYSE:USB). In total, 798,178 shares were sold, equating to a 0.6% reduction from its first-quarter stake. All told, Berkshire Hathaway still holds almost 128.9 million shares of U.S. Bancorp.</p>\n<p>If you're looking for a valid reason why 798,178 shares were sold during the second quarter, the best guess I can offer is Berkshire Hathaway wanting to keep away from the 10% ownership threshold for banks that would qualify it as a bank holding company (BHC). As a BHC, Berkshire's reporting and trading activity would be considerably more stringent than it is now. Perhaps Buffett was anticipating Berkshire's stake in U.S. Bancorp growing due to future buybacks.</p>\n<p>But like GM, it really doesn't matter why Buffett sold. Right now, U.S. Bancorp is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most attractive bank stocks investors can buy.</p>\n<p>To start with, it's consistently near the top or leading big banks in return on assets (ROA). Whereas most banks strive for a 1% ROA, U.S. Bancorp has a knack for delivering a 1.6% ROA, which is indicative of its fantastic management team. This is a company that's stuck true to the bread-and-butter of banking (i.e., loan and deposit growth), and has generally avoided the riskier derivative investment opportunities that ravaged money-center banks during the Great Recession.</p>\n<p>Furthermore, U.S. Bancorp is a banking leader when it comes to digital adoption. Approximately 79% of its customers were active digitally (online or mobile) in the May-ended quarter, which is up 7 percentage points from the comparable quarter two years prior. What's more, nearly two-thirds of all loan sales were completed online or via mobile app since 2021 began.</p>\n<p>As one of the nation's most efficient banks, U.S. Bancorp is set to thrive as the U.S. economic recovery takes shape.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F639553%2Fbiotech-lab-research-with-multiple-pipettes-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Bristol Myers Squibb</h3>\n<p>A third stock Berkshire Hathaway reduced in the second quarter is pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY). A little over 4.7 million shares were sold, which ultimately reduced Buffett's company's stake by 15% to roughly 26.3 million shares.</p>\n<p>Before diving into the \"why?\" part of the selling process, it's important to note that this position is almost certainly the responsibility of Buffett's investing lieutenants. The Oracle of Omaha has never had the interest or energy to keep up with clinical trials, which is a big reason he's generally avoided drugmakers over the years.</p>\n<p>As for why the Bristol Myers position was cut by 15%, there are two possible explanations. First, the company has stalled out around $70 a share on two previous occasions (1999 and 2016). With the company pushing back into the mid-$60 range in the second quarter, perhaps Combs and Weschler felt it was a prudent time to lock in some gains.</p>\n<p>The second possibility is that Bristol Myers Squibb was purchased as a coronavirus play, and it simply hasn't materialized as one.</p>\n<p>Not to sound like a broken record, but whatever the reasoning is, selling Bristol Myers Squibb at less than 9 times forward-year earnings is a mistake. This is a healthcare stock investors should be buying hand over fist.</p>\n<p>On the organic growth front, Bristol Myers is making waves. Eliquis, which was developed in combination with <b>Pfizer</b>, has become the leading oral anticoagulant and is on track for more than $10 billion in annual sales. Meanwhile, cancer immunotherapy Opdivo brought in $7 billion last year and is being examined in dozens of clinical trials as a monotherapy or combination treatment. Label expansion opportunities offer ample upside for Opdivo.</p>\n<p>Bristol Myers Squibb also turned heads with its 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene brought one of the world's top-selling cancer drugs, Revlimid, into the fold. Revlimid's annual sales have grown by a double-digit percentage for more than a decade, with the multiple myeloma drug benefiting from improved cancer-screening diagnostics, strong pricing power, increased duration of use, and label expansions. Since it's protected from a flood of generic competition until February 2026, Bristol Myers has a long runway to reap the rewards of its new cash cow.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over Fist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over Fist\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-18 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/18/3-stocks-buffett-is-selling-you-should-be-buying/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When it comes to investing prowess, Warren Buffett is in a class of his own. Since taking the helm of conglomerate Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965, he's helped deliver an average ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/18/3-stocks-buffett-is-selling-you-should-be-buying/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车","BRK.A":"伯克希尔","USB":"美国合众银行","BRK.B":"伯克希尔B"},"source_url":"https://www.fool.com/investing/2021/08/18/3-stocks-buffett-is-selling-you-should-be-buying/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160735178","content_text":"When it comes to investing prowess, Warren Buffett is in a class of his own. Since taking the helm of conglomerate Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965, he's helped deliver an average annual return to shareholders of 20%. That's 56 years and an average annual return of 20% over those 56 years! Taking into account the year-to-date gain from the Class A shares (BRK.A), Buffett has overseen a nearly 3,400,000% return in Berkshire Hathaway's stock while CEO.\nSuffice it to say, when Warren Buffett buys, adds to, reduces, or sells out of a stock, Wall Street and the investing community pay very close attention. On Monday, Aug. 16, investors received their latest peek under the hood.\n\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nBerkshire Hathaway was a net-seller of stocks in Q2\nCompanies and individuals managing at least $100 million in assets are required to file Form 13F with the Securities and Exchange Commission 45 days after a quarter has ended. A 13F provides a (dated) snapshot of what institutional investors, hedge funds, or market mavens were holding as of the end of the most recent quarter (June 30).\nBerkshire Hathaway's latest 13F showed a considerable amount of selling, rather than buying. In total, four stocks were purchased or added to during the second quarter, with the biggest buy being grocery chain Kroger. More than 10.7 million shares were added, boosting Berkshire Hathaway's stake to almost 61.8 million shares.\nOn the other hand, 11 stocks were reduced or completely given the heave-ho. Axalta Coating Systems, Berkshire Hathaway's only exposure to the materials sector, was completely sold. Additionally, the Oracle of Omaha and his investing team sent Biogen and Liberty Global (Class A, LBTYA) packing. Note, Berkshire still owns a reduced stake in Liberty Global's Class C shares (LBTYK).\nBut among the eight other holdings that were reduced are three stocks that investors should be buying hand over fist. Buffett and his investing lieutenants may have an impressive track record, but they're not infallible.\n\nThe all-electric 2022 Chevrolet Bolt EUV. Image source: General Motors.\nGeneral Motors\nFirst up is auto stock General Motors (NYSE:GM), which has been consistently trimmed in recent quarters. During the second quarter, Buffett and his team reduced Berkshire's GM stake by 7 million shares, leaving the company with 60 million shares.\nWhy reduce the General Motors stake? One possibility is persistent supply chain disruption caused by the coronavirus pandemic. Chip shortages have caused automakers to halt or reduce production of certain models, which should adversely affect their operating performance in the near term.\nAnother possible reason Buffett or his investing lieutenants, Todd Combs and Ted Weschler, may have chosen to lighten the load is GM's valuation. Since emerging from bankruptcy over a decade ago, GM's market cap was never higher than it was during the second quarter (a peak of $92 billion).\nBut whatever the reasoning is, selling shares of General Motors isn't a smart move. If anything, General Motors is more attractive now than it's been in over a decade. That's because it's going to benefit from a multi-decade vehicle replacement cycle as consumers and enterprises go electric.\nIn mid-June, General Motors announced its plans to up spending on electric vehicles (EV), autonomous vehicles, and battery technology to $35 billion through 2025. That's a 75% increase from its previous spending commitment on clean-energy solutions from prior to the pandemic. The expectation is that GM will launch 30 new EVs worldwide by mid-decade.\nGeneral Motors also has significant inroads in China, the world's largest auto market. With a number of established brands in the Chinese market and the infrastructure necessary to ramp up production, GM shouldn't have any issue gobbling up EV market share.\nCurrently valued at less than 8 times Wall Street's earnings-per-share forecast for 2022, GM is a screaming buy.\n\nImage source: U.S. Bank (U.S. Bancorp is U.S. Bank's parent company).\nU.S. Bancorp\nAnother surefire winner that was, once again, reduced very modestly by Buffett and his team during the quarter is regional bank stock U.S. Bancorp (NYSE:USB). In total, 798,178 shares were sold, equating to a 0.6% reduction from its first-quarter stake. All told, Berkshire Hathaway still holds almost 128.9 million shares of U.S. Bancorp.\nIf you're looking for a valid reason why 798,178 shares were sold during the second quarter, the best guess I can offer is Berkshire Hathaway wanting to keep away from the 10% ownership threshold for banks that would qualify it as a bank holding company (BHC). As a BHC, Berkshire's reporting and trading activity would be considerably more stringent than it is now. Perhaps Buffett was anticipating Berkshire's stake in U.S. Bancorp growing due to future buybacks.\nBut like GM, it really doesn't matter why Buffett sold. Right now, U.S. Bancorp is one of the most attractive bank stocks investors can buy.\nTo start with, it's consistently near the top or leading big banks in return on assets (ROA). Whereas most banks strive for a 1% ROA, U.S. Bancorp has a knack for delivering a 1.6% ROA, which is indicative of its fantastic management team. This is a company that's stuck true to the bread-and-butter of banking (i.e., loan and deposit growth), and has generally avoided the riskier derivative investment opportunities that ravaged money-center banks during the Great Recession.\nFurthermore, U.S. Bancorp is a banking leader when it comes to digital adoption. Approximately 79% of its customers were active digitally (online or mobile) in the May-ended quarter, which is up 7 percentage points from the comparable quarter two years prior. What's more, nearly two-thirds of all loan sales were completed online or via mobile app since 2021 began.\nAs one of the nation's most efficient banks, U.S. Bancorp is set to thrive as the U.S. economic recovery takes shape.\n\nImage source: Getty Images.\nBristol Myers Squibb\nA third stock Berkshire Hathaway reduced in the second quarter is pharmaceutical giant Bristol Myers Squibb (NYSE:BMY). A little over 4.7 million shares were sold, which ultimately reduced Buffett's company's stake by 15% to roughly 26.3 million shares.\nBefore diving into the \"why?\" part of the selling process, it's important to note that this position is almost certainly the responsibility of Buffett's investing lieutenants. The Oracle of Omaha has never had the interest or energy to keep up with clinical trials, which is a big reason he's generally avoided drugmakers over the years.\nAs for why the Bristol Myers position was cut by 15%, there are two possible explanations. First, the company has stalled out around $70 a share on two previous occasions (1999 and 2016). With the company pushing back into the mid-$60 range in the second quarter, perhaps Combs and Weschler felt it was a prudent time to lock in some gains.\nThe second possibility is that Bristol Myers Squibb was purchased as a coronavirus play, and it simply hasn't materialized as one.\nNot to sound like a broken record, but whatever the reasoning is, selling Bristol Myers Squibb at less than 9 times forward-year earnings is a mistake. This is a healthcare stock investors should be buying hand over fist.\nOn the organic growth front, Bristol Myers is making waves. Eliquis, which was developed in combination with Pfizer, has become the leading oral anticoagulant and is on track for more than $10 billion in annual sales. Meanwhile, cancer immunotherapy Opdivo brought in $7 billion last year and is being examined in dozens of clinical trials as a monotherapy or combination treatment. Label expansion opportunities offer ample upside for Opdivo.\nBristol Myers Squibb also turned heads with its 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene brought one of the world's top-selling cancer drugs, Revlimid, into the fold. Revlimid's annual sales have grown by a double-digit percentage for more than a decade, with the multiple myeloma drug benefiting from improved cancer-screening diagnostics, strong pricing power, increased duration of use, and label expansions. Since it's protected from a flood of generic competition until February 2026, Bristol Myers has a long runway to reap the rewards of its new cash cow.","news_type":1},"isVote":1,"tweetType":1,"viewCount":322,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892488985,"gmtCreate":1628683856647,"gmtModify":1631889860025,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/892488985","repostId":"2158186289","repostType":4,"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898399845,"gmtCreate":1628472161587,"gmtModify":1631889860036,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"likee","listText":"likee","text":"likee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/898399845","repostId":"1136322726","repostType":4,"isVote":1,"tweetType":1,"viewCount":232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":891155674,"gmtCreate":1628354217998,"gmtModify":1631889860042,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"yay","listText":"yay","text":"yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/891155674","repostId":"1139912651","repostType":4,"isVote":1,"tweetType":1,"viewCount":324,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893155774,"gmtCreate":1628249746898,"gmtModify":1631889860063,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"yay","listText":"yay","text":"yay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/893155774","repostId":"1180256775","repostType":4,"repost":{"id":"1180256775","kind":"news","pubTimestamp":1628249356,"share":"https://www.laohu8.com/m/news/1180256775?lang=&edition=full","pubTime":"2021-08-06 19:29","market":"us","language":"en","title":"DraftKings EPS misses by $0.18, beats on revenue, boosts full year revenue guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1180256775","media":"seekingalpha","summary":"DraftKings: Q2 Non-GAAP EPS of -$0.26; GAAP EPS of -$0.76misses by $0.18.\nRevenue of $298M (+320.1% ","content":"<p>DraftKings: Q2 Non-GAAP EPS of -$0.26; GAAP EPS of -$0.76misses by $0.18.</p>\n<p>Revenue of $298M (+320.1% Y/Y)beats by $50.78M.</p>\n<p>Monthly Unique Payers for B2C segment increased 281% compared to the second quarter of 2020.</p>\n<p>Average Revenue per MUP was $80 in the second quarter of 2021 representing a 26% increase versus the same period in 2020.</p>\n<p>The company is raising its FY2021 revenue guidance from a range of $1.05M-$1.15B to a range of $1.21B-$1.29B vs. consensus of $1.18B.</p>\n<p>DraftKings&nbsp;jumped&nbsp;nearly&nbsp;5%&nbsp;in&nbsp;premarket&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/50a797dacb799030e93d798a213459a5\" tg-width=\"800\" tg-height=\"560\" width=\"100%\" height=\"auto\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DraftKings EPS misses by $0.18, beats on revenue, boosts full year revenue guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDraftKings EPS misses by $0.18, beats on revenue, boosts full year revenue guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-06 19:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3726882-draftkings-eps-misses-by-018-beats-on-revenue-boosts-full-year-revenue-guidance><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>DraftKings: Q2 Non-GAAP EPS of -$0.26; GAAP EPS of -$0.76misses by $0.18.\nRevenue of $298M (+320.1% Y/Y)beats by $50.78M.\nMonthly Unique Payers for B2C segment increased 281% compared to the second ...</p>\n\n<a href=\"https://seekingalpha.com/news/3726882-draftkings-eps-misses-by-018-beats-on-revenue-boosts-full-year-revenue-guidance\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DKNG":"DraftKings Inc."},"source_url":"https://seekingalpha.com/news/3726882-draftkings-eps-misses-by-018-beats-on-revenue-boosts-full-year-revenue-guidance","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1180256775","content_text":"DraftKings: Q2 Non-GAAP EPS of -$0.26; GAAP EPS of -$0.76misses by $0.18.\nRevenue of $298M (+320.1% Y/Y)beats by $50.78M.\nMonthly Unique Payers for B2C segment increased 281% compared to the second quarter of 2020.\nAverage Revenue per MUP was $80 in the second quarter of 2021 representing a 26% increase versus the same period in 2020.\nThe company is raising its FY2021 revenue guidance from a range of $1.05M-$1.15B to a range of $1.21B-$1.29B vs. consensus of $1.18B.\nDraftKings jumped nearly 5% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":297,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804774234,"gmtCreate":1627985070728,"gmtModify":1631889860071,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"wah","listText":"wah","text":"wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804774234","repostId":"2156100119","repostType":4,"repost":{"id":"2156100119","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1627983900,"share":"https://www.laohu8.com/m/news/2156100119?lang=&edition=full","pubTime":"2021-08-03 17:45","market":"us","language":"en","title":"August is among the worst months of year for the stock market. Here's how to play it.","url":"https://stock-news.laohu8.com/highlight/detail?id=2156100119","media":"Dow Jones","summary":"On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulenc","content":"<p>On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.</p>\n<p>The month is associated with the worst performances for the Dow Jones Industrial Average , S&amp;P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.</p>\n<p>The research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.</p>\n<p>To be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.</p>\n<p>However, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&amp;P 500, doesn't mean the long-term trend has changed.</p>\n<p>\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.</p>\n<p>Check out the monthly returns on average since 1950:</p>\n<p>Here are the historical rankings by month via LPL:</p>\n<p>The folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.</p>\n<p>\"Since 1983, the weakest August returns tend to come in years where the S&amp;P 500 was up over 10% YTD heading into the month,\" the researchers note.</p>\n<p>The markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .</p>\n<p><b>So how to play the turbulent stretch?</b></p>\n<p>Jeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.</p>\n<p>\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.</p>\n<p>\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.</p>\n<p>Stock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"</p>\n<p>\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&amp;P 500 sees a push to the 4500-4600 range or even higher.</p>\n<p>Strategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.</p>\n<p>Bespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.</p>\n<p>\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>August is among the worst months of year for the stock market. Here's how to play it.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAugust is among the worst months of year for the stock market. Here's how to play it.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-03 17:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.</p>\n<p>The month is associated with the worst performances for the Dow Jones Industrial Average , S&amp;P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.</p>\n<p>The research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.</p>\n<p>To be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.</p>\n<p>However, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&amp;P 500, doesn't mean the long-term trend has changed.</p>\n<p>\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.</p>\n<p>Check out the monthly returns on average since 1950:</p>\n<p>Here are the historical rankings by month via LPL:</p>\n<p>The folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.</p>\n<p>\"Since 1983, the weakest August returns tend to come in years where the S&amp;P 500 was up over 10% YTD heading into the month,\" the researchers note.</p>\n<p>The markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .</p>\n<p><b>So how to play the turbulent stretch?</b></p>\n<p>Jeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.</p>\n<p>\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.</p>\n<p>\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.</p>\n<p>Stock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"</p>\n<p>\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&amp;P 500 sees a push to the 4500-4600 range or even higher.</p>\n<p>Strategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.</p>\n<p>Bespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.</p>\n<p>\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SSO":"两倍做多标普500ETF","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","UPRO":"三倍做多标普500ETF","IVV":"标普500指数ETF",".SPX":"S&P 500 Index","SH":"标普500反向ETF","OEX":"标普100"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156100119","content_text":"On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.\nThe month is associated with the worst performances for the Dow Jones Industrial Average , S&P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.\nThe research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.\nTo be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.\nHowever, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&P 500, doesn't mean the long-term trend has changed.\n\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.\nCheck out the monthly returns on average since 1950:\nHere are the historical rankings by month via LPL:\nThe folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.\n\"Since 1983, the weakest August returns tend to come in years where the S&P 500 was up over 10% YTD heading into the month,\" the researchers note.\nThe markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .\nSo how to play the turbulent stretch?\nJeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.\n\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.\n\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.\nStock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"\n\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&P 500 sees a push to the 4500-4600 range or even higher.\nStrategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.\nBespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.\n\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.","news_type":1},"isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804772539,"gmtCreate":1627984888021,"gmtModify":1631889860088,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"wah","listText":"wah","text":"wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804772539","repostId":"2156100119","repostType":4,"repost":{"id":"2156100119","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1627983900,"share":"https://www.laohu8.com/m/news/2156100119?lang=&edition=full","pubTime":"2021-08-03 17:45","market":"us","language":"en","title":"August is among the worst months of year for the stock market. Here's how to play it.","url":"https://stock-news.laohu8.com/highlight/detail?id=2156100119","media":"Dow Jones","summary":"On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulenc","content":"<p>On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.</p>\n<p>The month is associated with the worst performances for the Dow Jones Industrial Average , S&amp;P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.</p>\n<p>The research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.</p>\n<p>To be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.</p>\n<p>However, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&amp;P 500, doesn't mean the long-term trend has changed.</p>\n<p>\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.</p>\n<p>Check out the monthly returns on average since 1950:</p>\n<p>Here are the historical rankings by month via LPL:</p>\n<p>The folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.</p>\n<p>\"Since 1983, the weakest August returns tend to come in years where the S&amp;P 500 was up over 10% YTD heading into the month,\" the researchers note.</p>\n<p>The markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .</p>\n<p><b>So how to play the turbulent stretch?</b></p>\n<p>Jeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.</p>\n<p>\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.</p>\n<p>\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.</p>\n<p>Stock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"</p>\n<p>\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&amp;P 500 sees a push to the 4500-4600 range or even higher.</p>\n<p>Strategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.</p>\n<p>Bespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.</p>\n<p>\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>August is among the worst months of year for the stock market. Here's how to play it.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAugust is among the worst months of year for the stock market. Here's how to play it.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-03 17:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.</p>\n<p>The month is associated with the worst performances for the Dow Jones Industrial Average , S&amp;P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.</p>\n<p>The research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.</p>\n<p>To be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.</p>\n<p>However, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&amp;P 500, doesn't mean the long-term trend has changed.</p>\n<p>\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.</p>\n<p>Check out the monthly returns on average since 1950:</p>\n<p>Here are the historical rankings by month via LPL:</p>\n<p>The folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.</p>\n<p>\"Since 1983, the weakest August returns tend to come in years where the S&amp;P 500 was up over 10% YTD heading into the month,\" the researchers note.</p>\n<p>The markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .</p>\n<p><b>So how to play the turbulent stretch?</b></p>\n<p>Jeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.</p>\n<p>\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.</p>\n<p>\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.</p>\n<p>Stock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"</p>\n<p>\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&amp;P 500 sees a push to the 4500-4600 range or even higher.</p>\n<p>Strategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.</p>\n<p>Bespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.</p>\n<p>\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SSO":"两倍做多标普500ETF","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","UPRO":"三倍做多标普500ETF","IVV":"标普500指数ETF",".SPX":"S&P 500 Index","SH":"标普500反向ETF","OEX":"标普100"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156100119","content_text":"On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.\nThe month is associated with the worst performances for the Dow Jones Industrial Average , S&P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.\nThe research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.\nTo be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.\nHowever, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&P 500, doesn't mean the long-term trend has changed.\n\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.\nCheck out the monthly returns on average since 1950:\nHere are the historical rankings by month via LPL:\nThe folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.\n\"Since 1983, the weakest August returns tend to come in years where the S&P 500 was up over 10% YTD heading into the month,\" the researchers note.\nThe markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .\nSo how to play the turbulent stretch?\nJeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.\n\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.\n\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.\nStock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"\n\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&P 500 sees a push to the 4500-4600 range or even higher.\nStrategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.\nBespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.\n\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.","news_type":1},"isVote":1,"tweetType":1,"viewCount":216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":805580995,"gmtCreate":1627891862817,"gmtModify":1631889860095,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"wowew","listText":"wowew","text":"wowew","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/805580995","repostId":"1188442648","repostType":4,"repost":{"id":"1188442648","kind":"news","pubTimestamp":1627890543,"share":"https://www.laohu8.com/m/news/1188442648?lang=&edition=full","pubTime":"2021-08-02 15:49","market":"other","language":"en","title":"Commodities Week Ahead: Oil, Gold Eye U.S. Jobs Report As China PMI Slides","url":"https://stock-news.laohu8.com/highlight/detail?id=1188442648","media":"investing.com","summary":"It’s that time again. The release of the monthly US jobs report. And the direction of gold, oil and ","content":"<p>It’s that time again. The release of the monthly&nbsp;US jobs report. And the direction of&nbsp;gold,&nbsp;oil&nbsp;and a few other key commodities could well depend on how healthy the labor market in the world’s leading economy is.</p>\n<p>It can be argued that every US jobs report holds markets hostage 'til its release.</p>\n<p>But this report for July might be unusually important for three reasons: One, it will show how well America is hiring amid suspicion that government aid for the unemployed is keeping many from getting jobs; two, it will be a referendum on the US economy amid the resurgence of COVID cases from the Delta variant of the virus; and three, it will also demonstrate if the United States will assure the world of growth just as China’s economy was slacking.</p>\n<p>China's&nbsp;factory data, released on Monday, showed activity expanded in July at the slowest pace in 17 months as higher raw material costs, equipment maintenance and extreme weather weighed on business activity.&nbsp; The data added to concerns about a slowdown in the world's second-biggest economy.</p>\n<p><img src=\"https://static.tigerbbs.com/7e4e598a6558955419506b0cfefc5975\" tg-width=\"816\" tg-height=\"744\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Oil Weekly TTM</p>\n<p>Edward Moya, senior analyst at OANDA, said oil prices, particularly, were sensitive to talk of any China slowdown, adding:</p>\n<blockquote>\n \"China's been leading economic recovery in Asia and if the pullback deepens, concerns will grow that the global outlook will see a significant decline.\"The crude demand outlook is on shaky ground and that probably will not improve until global vaccinations improve.\"\n</blockquote>\n<p>New York-traded West Texas Intermediate crude and London’s&nbsp;Brentwere both down about 1% each in Monday’s afternoon trade in Asia, after posting modest gains for July, making it oil’s positive run to a fourth straight month.</p>\n<p>Also weighing on oil was a Reuters survey that found production from the Organization of the Petroleum Exporting Countries hitting 16 month highs last month as the group further eased production curbs under a pact with its allies and top exporter Saudi Arabia.</p>\n<p>While coronavirus cases continue to climb globally, analysts said higher vaccination rates would limit the need for the harsh lockdowns that gutted demand during the peak of the pandemic last year. The United States will not lock down again to curb COVID-19 but \"things are going to get worse\" as the Delta variant fuels a surge in cases, mostly among the unvaccinated, top US infectious disease expert Anthony Fauci said Sunday.</p>\n<p>Hence, the importance of the July nonfarm payrolls report due Friday.</p>\n<p>Economists are expecting the economy to have added 900,000 jobs in July after a forecast-beating 850,000 in June.</p>\n<p>Last week Fed Chair Jerome Powell said the job market still had \"some ground to cover\" before it would be time to start scaling back stimulus measures the central bank enacted in the spring of 2020 to combat the economic fallout from the coronavirus pandemic.</p>\n<p>In June Fed officials began debating how to wind down bond purchases, but there is no clear timetable yet for when it will begin pulling back emergency market support measures.</p>\n<p><b>Treacherous Waters For Gold If Jobs Numbers Surprise</b></p>\n<p>Oil aside, gold and&nbsp;copper&nbsp;will also likely be heavily influenced by the July payrolls report.</p>\n<p>After two weeks of anemic action, gold longs got a break last week when Federal Reserve Chair Jerome Powell said the central bank wasn’t ready to raise US interest rates as it was still focused on buying assets to support an economy recovering from the coronavirus pandemic.</p>\n<p>Powell also refused to discuss when the Fed might consider tapering the combined $120 billion it was plonking down each month into Treasury bonds and agency mortgage‑backed securities. His mantra: It wasn’t time for that.</p>\n<p><img src=\"https://static.tigerbbs.com/3ef5b83aa16320d74287cd6de18a59bd\" tg-width=\"853\" tg-height=\"746\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\">Gold Weekly TTM</p>\n<p>Front-month gold on New York’s Comex was down 0.2% in Monday’s afternoon trade in Asia, hovering at under $1,815 an ounce.</p>\n<p>If gold clears $1,850, it might be able to make a run toward $1,900, analysts say.</p>\n<p>The risk, however, is US jobs showing a bigger-than-expected gain for July in the Labor Department’s monthly nonfarm payroll report due at the end of this week. If that overshoots forecasts, it could complicate the Fed’s aim of keeping the stimulus on for the foreseeable future and rates lower for longer. Gold might be caught in treacherous waters again if the job numbers surprise.</p>\n<p>Aside from the jobs report, the economic calendar also features other important data including the Institute for Supply Management’s&nbsp;manufacturing&nbsp;data Monday and&nbsp;service sector&nbsp;data on Wednesday. The ISM manufacturing PMI is expected to remain robust, but to again underline supply side strains in the economy that are contributing to higherinflation.</p>\n<p>Data on&nbsp;factory orders&nbsp;is slated for Tuesday and the weekly report oninitial jobless claimsis on Thursday. Jobless claims have fallen considerably since the start of the year amid growing labor demand, but the Delta variant that’s fueled a recent surge in new infections across the country poses a risk.</p>\n<p>Several Fed officials are also scheduled to speak during the week, including Boston Fed President Eric Rosengren, Fed Vice Chair&nbsp;Richard Clarida&nbsp;and Fed Governor&nbsp;Christopher Waller.</p>","source":"lsy1594375853987","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Commodities Week Ahead: Oil, Gold Eye U.S. Jobs Report As China PMI Slides</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCommodities Week Ahead: Oil, Gold Eye U.S. Jobs Report As China PMI Slides\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-02 15:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investing.com/analysis/commodities-week-ahead-oil-gold-eye-us-jobs-report-as-china-pmi-slides-200595381><strong>investing.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It’s that time again. The release of the monthly US jobs report. And the direction of gold, oil and a few other key commodities could well depend on how healthy the labor market in the world’s leading...</p>\n\n<a href=\"https://www.investing.com/analysis/commodities-week-ahead-oil-gold-eye-us-jobs-report-as-china-pmi-slides-200595381\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.investing.com/analysis/commodities-week-ahead-oil-gold-eye-us-jobs-report-as-china-pmi-slides-200595381","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188442648","content_text":"It’s that time again. The release of the monthly US jobs report. And the direction of gold, oil and a few other key commodities could well depend on how healthy the labor market in the world’s leading economy is.\nIt can be argued that every US jobs report holds markets hostage 'til its release.\nBut this report for July might be unusually important for three reasons: One, it will show how well America is hiring amid suspicion that government aid for the unemployed is keeping many from getting jobs; two, it will be a referendum on the US economy amid the resurgence of COVID cases from the Delta variant of the virus; and three, it will also demonstrate if the United States will assure the world of growth just as China’s economy was slacking.\nChina's factory data, released on Monday, showed activity expanded in July at the slowest pace in 17 months as higher raw material costs, equipment maintenance and extreme weather weighed on business activity.  The data added to concerns about a slowdown in the world's second-biggest economy.\nOil Weekly TTM\nEdward Moya, senior analyst at OANDA, said oil prices, particularly, were sensitive to talk of any China slowdown, adding:\n\n \"China's been leading economic recovery in Asia and if the pullback deepens, concerns will grow that the global outlook will see a significant decline.\"The crude demand outlook is on shaky ground and that probably will not improve until global vaccinations improve.\"\n\nNew York-traded West Texas Intermediate crude and London’s Brentwere both down about 1% each in Monday’s afternoon trade in Asia, after posting modest gains for July, making it oil’s positive run to a fourth straight month.\nAlso weighing on oil was a Reuters survey that found production from the Organization of the Petroleum Exporting Countries hitting 16 month highs last month as the group further eased production curbs under a pact with its allies and top exporter Saudi Arabia.\nWhile coronavirus cases continue to climb globally, analysts said higher vaccination rates would limit the need for the harsh lockdowns that gutted demand during the peak of the pandemic last year. The United States will not lock down again to curb COVID-19 but \"things are going to get worse\" as the Delta variant fuels a surge in cases, mostly among the unvaccinated, top US infectious disease expert Anthony Fauci said Sunday.\nHence, the importance of the July nonfarm payrolls report due Friday.\nEconomists are expecting the economy to have added 900,000 jobs in July after a forecast-beating 850,000 in June.\nLast week Fed Chair Jerome Powell said the job market still had \"some ground to cover\" before it would be time to start scaling back stimulus measures the central bank enacted in the spring of 2020 to combat the economic fallout from the coronavirus pandemic.\nIn June Fed officials began debating how to wind down bond purchases, but there is no clear timetable yet for when it will begin pulling back emergency market support measures.\nTreacherous Waters For Gold If Jobs Numbers Surprise\nOil aside, gold and copper will also likely be heavily influenced by the July payrolls report.\nAfter two weeks of anemic action, gold longs got a break last week when Federal Reserve Chair Jerome Powell said the central bank wasn’t ready to raise US interest rates as it was still focused on buying assets to support an economy recovering from the coronavirus pandemic.\nPowell also refused to discuss when the Fed might consider tapering the combined $120 billion it was plonking down each month into Treasury bonds and agency mortgage‑backed securities. His mantra: It wasn’t time for that.\nGold Weekly TTM\nFront-month gold on New York’s Comex was down 0.2% in Monday’s afternoon trade in Asia, hovering at under $1,815 an ounce.\nIf gold clears $1,850, it might be able to make a run toward $1,900, analysts say.\nThe risk, however, is US jobs showing a bigger-than-expected gain for July in the Labor Department’s monthly nonfarm payroll report due at the end of this week. If that overshoots forecasts, it could complicate the Fed’s aim of keeping the stimulus on for the foreseeable future and rates lower for longer. Gold might be caught in treacherous waters again if the job numbers surprise.\nAside from the jobs report, the economic calendar also features other important data including the Institute for Supply Management’s manufacturing data Monday and service sector data on Wednesday. The ISM manufacturing PMI is expected to remain robust, but to again underline supply side strains in the economy that are contributing to higherinflation.\nData on factory orders is slated for Tuesday and the weekly report oninitial jobless claimsis on Thursday. Jobless claims have fallen considerably since the start of the year amid growing labor demand, but the Delta variant that’s fueled a recent surge in new infections across the country poses a risk.\nSeveral Fed officials are also scheduled to speak during the week, including Boston Fed President Eric Rosengren, Fed Vice Chair Richard Clarida and Fed Governor Christopher Waller.","news_type":1},"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808620289,"gmtCreate":1627574741841,"gmtModify":1631889860115,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/808620289","repostId":"1131613450","repostType":4,"repost":{"id":"1131613450","kind":"news","pubTimestamp":1627570012,"share":"https://www.laohu8.com/m/news/1131613450?lang=&edition=full","pubTime":"2021-07-29 22:46","market":"us","language":"en","title":"Facebook Metaverse, Next Wave Of Growth Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=1131613450","media":"seekingalpha","summary":"Summary\n\nMark Zuckerberg discusses metaverse, and why this is the future for Facebook.\nFacebook's Q2","content":"<p><b>Summary</b></p>\n<ul>\n <li>Mark Zuckerberg discusses metaverse, and why this is the future for Facebook.</li>\n <li>Facebook's Q2 2021 results were sizzling hot as it comps an easy period last year.</li>\n <li>Facebook remains very attractively priced, growing at +25% CAGR and priced at 9x sales.</li>\n</ul>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/dcbdc2d6bd0c7b42c807ae560b621aa3\" tg-width=\"1536\" tg-height=\"987\" width=\"100%\" height=\"auto\"><span>atakan/iStock via Getty Images</span></p>\n<p><b>Investment Thesis</b></p>\n<p>Facebook (FB) is still a growth engine with its top-line growing 54% y/y. What's more, as we look ahead, despite the tough comps for H2, Facebook is still likely to grow by at least 25% y/y.</p>\n<p>Further, unlike countless other social media companies, Facebook is unquestionably one of the best money printing companies.</p>\n<p>Facebook's stock is trading for approximately 9x sales. Ultimately, there simply aren't many companies with so much dominance still growing at such a rapid rate priced as cheaply as Facebook. This investment is very attractive.</p>\n<p><b>Revenue Growth Rates Are Impressively High</b></p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/bae2630474c1ccf97169b03a39be3b97\" tg-width=\"640\" tg-height=\"285\" width=\"100%\" height=\"auto\"><span>Source: author's calculations</span></p>\n<p>As you can see above, Facebook's Q2 2021 revenue was up 56% y/y. Having said that, this strong performance in H1 2021 was mostly to be expected, given the easier comps with the same period a year ago.</p>\n<p>However, as we look ahead, considering a 2-year stacked period, where Facebook gets normalized for the COVID period, H2 2021 is expected to decelerate modestly.<i>How modestly?</i>This is the critical question that's very difficult to parse out from Facebook's commentary.</p>\n<p>On the one hand, we know that Facebook has a long history of being incredibly conservative. While on the other hand, we have to factor in the unavoidable uncertainty from iOS privacy updates, as well as, a difficult regulatory environment, most notably in Europe with transatlantic data transfers.</p>\n<p>Altogether, I believe that H2 2021 is likely to continue growing at approximately 25% CAGR. This is a meaningful slowdown from what we saw in H1 2021 but given Facebook's scale, for it to still be able out a mid-20s% CAGR it's praiseworthy.</p>\n<p>Consequently, we can assume that Facebook will likely print $120 billion in revenues in 2021. However, Facebook makes it clear that it's not resting on its laurels, but that it's going to meaningfully invest in the next chapter of its growth story.</p>\n<p><b>Facebook's Next Wave of Growth Opportunities</b></p>\n<p>Facebook is doubling down into making videos the focal point of content creation. Video now accounts for nearly half of all time spent on Facebook, while Reels (TikTok clone) is its largest contributor to engagement growth on Instagram.</p>\n<p>Furthermore, consistent with Facebook's previous messaging to investors, Facebook is now giving creators more ways to monetize their content.</p>\n<p>While Facebook's push into video monetization is different from Twitter's (TWTR) offering, Facebook has taken a leaf from Twitter Spaces, and Facebook is now making a push into audio channels with its Live Audio Rooms.</p>\n<p>Next, Facebook is looking forward to making commerce a bigger part of its family of apps. Facebook is investing in its marketplace solution for businesses to customize their offering on the platform, as Facebook makes businesses' products or services easier to surface.</p>\n<p>Facebook is wanting to improve both customers' and businesses' experience on its platform. But Facebook admits that this is going to take a long time for it to reach a meaningful scale, as its advertising business is so big and accounts for close to 99% of total revenue.</p>\n<p>Accordingly, even its commerce business was to compound at very rapid rates, it would probably still take more than 5 years before a needle-moving revenue source is derived from this opportunity.</p>\n<p>The third area that Facebook believes will drive meaningful growth opportunities is metaverse. So what is the metaverse? This is how CEO Mark Zuckerberg&nbsp;explained&nbsp;it:</p>\n<blockquote>\n <i>It's a virtual environment. We can be present with people in digital spaces. And you can kind of think about this is an embodied Internet that you're inside of rather than just looking at.</i>\n</blockquote>\n<p>This layers augmented reality onto any device offering users a fully immersive virtual experience. The key theme is the broadness of this technology. Going beyond simply communicating with others, users will be able to be present to create, game, exercise, and transact with others.</p>\n<p>Needless to say that all this effort into these products will require meaningful capital investment over a multi-year period, with Facebook's CFO Dave Wehner declare on the call that billions will have to be invested.</p>\n<p>Nonetheless, the stock is clearly very reasonably valued.</p>\n<p><b>Valuation - Very High Quality and Attractively Priced</b></p>\n<p><img src=\"https://static.tigerbbs.com/97a338fa8c3cfa7870d4f7873029655c\" tg-width=\"640\" tg-height=\"382\" width=\"100%\" height=\"auto\"></p>\n<p>Every time I cover Facebook I ask readers to find me a business that has free cash flow margins of 29%. I'm still waiting for a response.</p>\n<p>This implies that for every $1 of revenues, after everything is said and done, Facebook takes out 29 cents in cash. This is cash that gets put directly on its balance sheet or used to repurchase stock.</p>\n<p>Incidentally, to put this cash movement in context, consider the following: Facebook's free cash flow during Q2 2021 reached $8.5 billion. Of that, Facebook repurchased $7 billion worth of stock.</p>\n<p>Investors often retort that Facebook's free cash flow is so strong, because of its heavy stock-based compensation. To that insight, I remark that stock-based compensation is already factored into its market cap valuation.</p>\n<p>Hence, when investors are asked to pay 9x sales for Facebook, investors are already factoring in its stock-based compensation.</p>\n<p>You are welcome to look far and wide, you won't find many businesses growing at 25% CAGR, highly free cash flow generative, priced at 9x sales. If you do, please reach out to me.</p>\n<p><b>The Bottom Line</b></p>\n<p>Facebook continues to plow ahead at an unstoppable pace.</p>\n<p>The commentary around its future growth opportunities was optimistic and honest. While noting that there's a huge opportunity to strengthen user and businesses engagement with Facebook's family of apps, Zuckerberg several times noted that these projects are starting from a very small scale and it will take a long time until they become meaningful contributors to its revenue growth rates.</p>\n<p>Having said that, at 9x sales for a company that's likely to grow at 25% CAGR this year, this stock is incredibly cheaply valued, even after the impressive run the stock has had over the past year.</p>\n<p>However, given the cheapness of many small-cap stocks right now, while nowhere near as dominant and profitable as Facebook, I'm nevertheless going to stick around with those small businesses that are even more attractively priced to me. Happy investing!</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Facebook Metaverse, Next Wave Of Growth Opportunities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFacebook Metaverse, Next Wave Of Growth Opportunities\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-29 22:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4442466-facebook-metaverse-next-wave-of-growth-opportunities><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nMark Zuckerberg discusses metaverse, and why this is the future for Facebook.\nFacebook's Q2 2021 results were sizzling hot as it comps an easy period last year.\nFacebook remains very ...</p>\n\n<a href=\"https://seekingalpha.com/article/4442466-facebook-metaverse-next-wave-of-growth-opportunities\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://seekingalpha.com/article/4442466-facebook-metaverse-next-wave-of-growth-opportunities","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131613450","content_text":"Summary\n\nMark Zuckerberg discusses metaverse, and why this is the future for Facebook.\nFacebook's Q2 2021 results were sizzling hot as it comps an easy period last year.\nFacebook remains very attractively priced, growing at +25% CAGR and priced at 9x sales.\n\natakan/iStock via Getty Images\nInvestment Thesis\nFacebook (FB) is still a growth engine with its top-line growing 54% y/y. What's more, as we look ahead, despite the tough comps for H2, Facebook is still likely to grow by at least 25% y/y.\nFurther, unlike countless other social media companies, Facebook is unquestionably one of the best money printing companies.\nFacebook's stock is trading for approximately 9x sales. Ultimately, there simply aren't many companies with so much dominance still growing at such a rapid rate priced as cheaply as Facebook. This investment is very attractive.\nRevenue Growth Rates Are Impressively High\nSource: author's calculations\nAs you can see above, Facebook's Q2 2021 revenue was up 56% y/y. Having said that, this strong performance in H1 2021 was mostly to be expected, given the easier comps with the same period a year ago.\nHowever, as we look ahead, considering a 2-year stacked period, where Facebook gets normalized for the COVID period, H2 2021 is expected to decelerate modestly.How modestly?This is the critical question that's very difficult to parse out from Facebook's commentary.\nOn the one hand, we know that Facebook has a long history of being incredibly conservative. While on the other hand, we have to factor in the unavoidable uncertainty from iOS privacy updates, as well as, a difficult regulatory environment, most notably in Europe with transatlantic data transfers.\nAltogether, I believe that H2 2021 is likely to continue growing at approximately 25% CAGR. This is a meaningful slowdown from what we saw in H1 2021 but given Facebook's scale, for it to still be able out a mid-20s% CAGR it's praiseworthy.\nConsequently, we can assume that Facebook will likely print $120 billion in revenues in 2021. However, Facebook makes it clear that it's not resting on its laurels, but that it's going to meaningfully invest in the next chapter of its growth story.\nFacebook's Next Wave of Growth Opportunities\nFacebook is doubling down into making videos the focal point of content creation. Video now accounts for nearly half of all time spent on Facebook, while Reels (TikTok clone) is its largest contributor to engagement growth on Instagram.\nFurthermore, consistent with Facebook's previous messaging to investors, Facebook is now giving creators more ways to monetize their content.\nWhile Facebook's push into video monetization is different from Twitter's (TWTR) offering, Facebook has taken a leaf from Twitter Spaces, and Facebook is now making a push into audio channels with its Live Audio Rooms.\nNext, Facebook is looking forward to making commerce a bigger part of its family of apps. Facebook is investing in its marketplace solution for businesses to customize their offering on the platform, as Facebook makes businesses' products or services easier to surface.\nFacebook is wanting to improve both customers' and businesses' experience on its platform. But Facebook admits that this is going to take a long time for it to reach a meaningful scale, as its advertising business is so big and accounts for close to 99% of total revenue.\nAccordingly, even its commerce business was to compound at very rapid rates, it would probably still take more than 5 years before a needle-moving revenue source is derived from this opportunity.\nThe third area that Facebook believes will drive meaningful growth opportunities is metaverse. So what is the metaverse? This is how CEO Mark Zuckerberg explained it:\n\nIt's a virtual environment. We can be present with people in digital spaces. And you can kind of think about this is an embodied Internet that you're inside of rather than just looking at.\n\nThis layers augmented reality onto any device offering users a fully immersive virtual experience. The key theme is the broadness of this technology. Going beyond simply communicating with others, users will be able to be present to create, game, exercise, and transact with others.\nNeedless to say that all this effort into these products will require meaningful capital investment over a multi-year period, with Facebook's CFO Dave Wehner declare on the call that billions will have to be invested.\nNonetheless, the stock is clearly very reasonably valued.\nValuation - Very High Quality and Attractively Priced\n\nEvery time I cover Facebook I ask readers to find me a business that has free cash flow margins of 29%. I'm still waiting for a response.\nThis implies that for every $1 of revenues, after everything is said and done, Facebook takes out 29 cents in cash. This is cash that gets put directly on its balance sheet or used to repurchase stock.\nIncidentally, to put this cash movement in context, consider the following: Facebook's free cash flow during Q2 2021 reached $8.5 billion. Of that, Facebook repurchased $7 billion worth of stock.\nInvestors often retort that Facebook's free cash flow is so strong, because of its heavy stock-based compensation. To that insight, I remark that stock-based compensation is already factored into its market cap valuation.\nHence, when investors are asked to pay 9x sales for Facebook, investors are already factoring in its stock-based compensation.\nYou are welcome to look far and wide, you won't find many businesses growing at 25% CAGR, highly free cash flow generative, priced at 9x sales. If you do, please reach out to me.\nThe Bottom Line\nFacebook continues to plow ahead at an unstoppable pace.\nThe commentary around its future growth opportunities was optimistic and honest. While noting that there's a huge opportunity to strengthen user and businesses engagement with Facebook's family of apps, Zuckerberg several times noted that these projects are starting from a very small scale and it will take a long time until they become meaningful contributors to its revenue growth rates.\nHaving said that, at 9x sales for a company that's likely to grow at 25% CAGR this year, this stock is incredibly cheaply valued, even after the impressive run the stock has had over the past year.\nHowever, given the cheapness of many small-cap stocks right now, while nowhere near as dominant and profitable as Facebook, I'm nevertheless going to stick around with those small businesses that are even more attractively priced to me. Happy investing!","news_type":1},"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808667743,"gmtCreate":1627574695982,"gmtModify":1633758124040,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/808667743","repostId":"1165497040","repostType":4,"repost":{"id":"1165497040","kind":"news","pubTimestamp":1627542522,"share":"https://www.laohu8.com/m/news/1165497040?lang=&edition=full","pubTime":"2021-07-29 15:08","market":"us","language":"en","title":"Amazon Reports Earnings Thursday. Expect a Blowout.","url":"https://stock-news.laohu8.com/highlight/detail?id=1165497040","media":"Barrons","summary":"Amazon reports earnings after Thursday’s closing bell. Expect a blowout.Another is that Amazon’s competitors have already reported solid numbers.Shopify, arguably one of the company’s most important rivals in e-commerce,posted better-than-expected results for the June quarter, noting that sustained digital commerce trends and U.S. stimulus checks in March and April drove revenues above expectations. Strong reports from Alphabet,Snap and Twitter suggest Amazon will post accelerating growth in its","content":"<p>Amazon reports earnings after Thursday’s closing bell. Expect a blowout.</p>\n<p>For the June quarter, the tech giant has projected sales of $110 billion to $116 billion, with operating income in the $4.5 billion-to-$8 billion range. Wall Street consensus calls for sales of $115.4 billion, operating income of $7.8 billion, and earnings of $12.28 a share.</p>\n<p>There are several reasons why the Street numbers might be too low.</p>\n<p>For one, Amazon (ticker: AMZN)&nbsp;has beat expectations&nbsp;in every quarter since the start of the pandemic—in fact, for 10 quarters in a row.</p>\n<p>Another is that Amazon’s competitors have already reported solid numbers.Shopify(SHOP), arguably one of the company’s most important rivals in e-commerce,posted better-than-expected results for the June quarter, noting that sustained digital commerce trends and U.S. stimulus checks in March and April drove revenues above expectations. Strong reports from&nbsp;Alphabet,Snap&nbsp;and&nbsp;Twitter&nbsp;suggest Amazon will post accelerating growth in its underappreciated advertising business. And the&nbsp;strength in the cloud business at Microsoft&nbsp;bodes well for Amazon Web Services.</p>\n<p>Street estimates call for Amazon to post $57.3 billion in online sales, up 25%; $24.8 billion in third-party sellers services, up 36%; $14.3 billion from AWS, up 32%; $7.9 billion in subscription services, up 36%; $7 billion in “other” revenue, which is mostly advertising, up 66%; and $3.9 billion in physical stores revenue, up 3%.</p>\n<p>Plus, there are a couple of other factors at play. This will be the first quarter for Amazon since Jeff Bezos turned over the CEO reins to Andy Jassy. Bezos didn’t typically participate in the company’s quarterly earnings calls with analysts, leaving that job to CFO Brian OIsavky; it remains to be seen if Jassy will make an appearance this year. Also, Amazon finds itself at the heart of the debate—in Washington and elsewhere—over the power of tech companies, and now faces an in-depth investigation by the Federal Trade Commission over&nbsp;its proposed acquisition of the film studio MGM.Amazon has requested&nbsp;that FTC Chair Lina Khan recuse herself from any matters involving Amazon given her past criticisms of the company.</p>\n<p></p>\n<p>Investors also will be watching for clues on how the company expects the pandemic and a return to a more normal economy will impact results for the rest of the year. Street estimates for the September quarter call for revenue of $118.6 billion and profits of $12.97 a share.</p>\n<p>In a research note, MKM Partners analyst Rohit Kulkarni points out that Amazon has underperformed both Alphabet and&nbsp;Facebook&nbsp;shares this year. He thinks the stock has been weighed down by ongoing debate about the true strength of this year’s&nbsp;Prime Day&nbsp;sales event, as well as ongoing questions about the outlook for e-commerce as supplemental U.S. unemployment benefits lapse in September. Nonetheless, Kulkarni thinks that advertising, Amazon Prime subscriptions, and AWS will together drive upside to both second-quarter results and guidance, and he continues to consider Amazon his best pick among the big internet stocks. Kulkarni keeps his Buy rating and $4,075 target price.</p>\n<p>Evercore ISI analyst Mark Mahaney maintains an Outperform rating and $4,500 target price. He thinks Street estimates for the second quarter “look largely reasonable,” although he has some concerns that the Street might be too bullish on the third quarter, in particular given Prime Day this year shifted into the second quarter.</p>\n<p>Monness Crespi White analyst Brian White notes that Amazon shares have been “range bound” over the past few months, but he thinks the company is “uniquely positioned” to exit the pandemic as one of the biggest beneficiaries of the digital transformation trend. White asserts that “the company’s growth path is very attractive across the e-commerce segment, AWS, digital media, advertising, Alexa and more.” White maintains his Buy rating and $4,500 target price.</p>\n<p>On Wednesday, Amazon shares were up 0.1%, to $3,630.32.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amazon Reports Earnings Thursday. Expect a Blowout.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmazon Reports Earnings Thursday. Expect a Blowout.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-29 15:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/amazon-earnings-51627497584?mod=hp_LEADSUPP_2><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Amazon reports earnings after Thursday’s closing bell. Expect a blowout.\nFor the June quarter, the tech giant has projected sales of $110 billion to $116 billion, with operating income in the $4.5 ...</p>\n\n<a href=\"https://www.barrons.com/articles/amazon-earnings-51627497584?mod=hp_LEADSUPP_2\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMZN":"亚马逊"},"source_url":"https://www.barrons.com/articles/amazon-earnings-51627497584?mod=hp_LEADSUPP_2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165497040","content_text":"Amazon reports earnings after Thursday’s closing bell. Expect a blowout.\nFor the June quarter, the tech giant has projected sales of $110 billion to $116 billion, with operating income in the $4.5 billion-to-$8 billion range. Wall Street consensus calls for sales of $115.4 billion, operating income of $7.8 billion, and earnings of $12.28 a share.\nThere are several reasons why the Street numbers might be too low.\nFor one, Amazon (ticker: AMZN) has beat expectations in every quarter since the start of the pandemic—in fact, for 10 quarters in a row.\nAnother is that Amazon’s competitors have already reported solid numbers.Shopify(SHOP), arguably one of the company’s most important rivals in e-commerce,posted better-than-expected results for the June quarter, noting that sustained digital commerce trends and U.S. stimulus checks in March and April drove revenues above expectations. Strong reports from Alphabet,Snap and Twitter suggest Amazon will post accelerating growth in its underappreciated advertising business. And the strength in the cloud business at Microsoft bodes well for Amazon Web Services.\nStreet estimates call for Amazon to post $57.3 billion in online sales, up 25%; $24.8 billion in third-party sellers services, up 36%; $14.3 billion from AWS, up 32%; $7.9 billion in subscription services, up 36%; $7 billion in “other” revenue, which is mostly advertising, up 66%; and $3.9 billion in physical stores revenue, up 3%.\nPlus, there are a couple of other factors at play. This will be the first quarter for Amazon since Jeff Bezos turned over the CEO reins to Andy Jassy. Bezos didn’t typically participate in the company’s quarterly earnings calls with analysts, leaving that job to CFO Brian OIsavky; it remains to be seen if Jassy will make an appearance this year. Also, Amazon finds itself at the heart of the debate—in Washington and elsewhere—over the power of tech companies, and now faces an in-depth investigation by the Federal Trade Commission over its proposed acquisition of the film studio MGM.Amazon has requested that FTC Chair Lina Khan recuse herself from any matters involving Amazon given her past criticisms of the company.\n\nInvestors also will be watching for clues on how the company expects the pandemic and a return to a more normal economy will impact results for the rest of the year. Street estimates for the September quarter call for revenue of $118.6 billion and profits of $12.97 a share.\nIn a research note, MKM Partners analyst Rohit Kulkarni points out that Amazon has underperformed both Alphabet and Facebook shares this year. He thinks the stock has been weighed down by ongoing debate about the true strength of this year’s Prime Day sales event, as well as ongoing questions about the outlook for e-commerce as supplemental U.S. unemployment benefits lapse in September. Nonetheless, Kulkarni thinks that advertising, Amazon Prime subscriptions, and AWS will together drive upside to both second-quarter results and guidance, and he continues to consider Amazon his best pick among the big internet stocks. Kulkarni keeps his Buy rating and $4,075 target price.\nEvercore ISI analyst Mark Mahaney maintains an Outperform rating and $4,500 target price. He thinks Street estimates for the second quarter “look largely reasonable,” although he has some concerns that the Street might be too bullish on the third quarter, in particular given Prime Day this year shifted into the second quarter.\nMonness Crespi White analyst Brian White notes that Amazon shares have been “range bound” over the past few months, but he thinks the company is “uniquely positioned” to exit the pandemic as one of the biggest beneficiaries of the digital transformation trend. White asserts that “the company’s growth path is very attractive across the e-commerce segment, AWS, digital media, advertising, Alexa and more.” White maintains his Buy rating and $4,500 target price.\nOn Wednesday, Amazon shares were up 0.1%, to $3,630.32.","news_type":1},"isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801367944,"gmtCreate":1627483488988,"gmtModify":1633764549231,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"commenting","listText":"commenting","text":"commenting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/801367944","repostId":"1179923360","repostType":4,"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177502759,"gmtCreate":1627234211971,"gmtModify":1633767007886,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"likee","listText":"likee","text":"likee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177502759","repostId":"2153878189","repostType":4,"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":174816401,"gmtCreate":1627090252103,"gmtModify":1633768108101,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/174816401","repostId":"2153980423","repostType":4,"isVote":1,"tweetType":1,"viewCount":222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175923926,"gmtCreate":1627003255665,"gmtModify":1633768893080,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"eow","listText":"eow","text":"eow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175923926","repostId":"1164478982","repostType":4,"repost":{"id":"1164478982","kind":"news","pubTimestamp":1626995319,"share":"https://www.laohu8.com/m/news/1164478982?lang=&edition=full","pubTime":"2021-07-23 07:08","market":"us","language":"en","title":"Wall Street ekes out gains, led by tech, growth stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1164478982","media":"Reuters","summary":"NEW YORK  - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks.A pull-back in economically sensitive cyclicals kept the S&P 500’s and the blue-chip Dow’s gains muted, while small-caps underperformed their larger rivals.“The market is flip-flopping between the view that economic growth has almost peaked so you need to buy stocks that manufacture thei","content":"<p>NEW YORK (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks.</p>\n<p>A pull-back in economically sensitive cyclicals kept the S&amp;P 500’s and the blue-chip Dow’s gains muted, while small-caps underperformed their larger rivals.</p>\n<p>But megacap tech and tech-adjacent stocks, such as Microsoft Corp, Amazon.com, Apple Inc, <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc and Alphabet Inc, rose ahead of their quarterly results next week, putting the Nasdaq out front.</p>\n<p>All three major U.S. stock indexes ended the session within 1% of their record closing highs.</p>\n<p>Growth stocks, which outperformed throughout the health crisis, were back in favor, gaining 0.8%, while the value index slipped by 0.5%.</p>\n<p>“The market is flip-flopping between the view that economic growth has almost peaked so you need to buy stocks that manufacture their own growth like tech names, versus the view that economic growth will continue and you want to own cyclicals and value names,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York.</p>\n<p>The number of U.S. workers filing first-time applications for unemployment benefits spiked unexpectedly to 419,000 last week, a two-month high, according to the Labor Department.</p>\n<p>Market participants are closely watching labor market indicators for hints as to when the Federal Reserve, expected to convene next week for its two-day monetary policy meeting, will begin discussions about hiking key interest rates from near zero.</p>\n<p>“The jobless data today didn’t have a meaningful impact on markets or the economic outlook,” Carter added. “It’s now all about how much longer the Fed will tolerate low rates. The Fed seems to be favoring its full employment mandate more than its price stability mandate.”</p>\n<p>“Accordingly, the upcoming Fed meeting could be impactful,” Carter said.</p>\n<p>Benchmark Treasury yields eased after the bid at the largest-ever TIPS auction touched a record low, pressuring rate sensitive banks.</p>\n<p>The Dow Jones Industrial Average rose 25.35 points, or 0.07%, to 34,823.35, the S&amp;P 500 gained 8.79 points, or 0.20%, to 4,367.48 and the Nasdaq Composite added 52.64 points, or 0.36%, to 14,684.60.</p>\n<p>Of the 11 major sectors of the S&amp;P 500, tech was shining brightest, gaining 0.7%. Energy stocks suffered the largest percentage drop.</p>\n<p>The second-quarter reporting season barreled ahead at full-throttle, with 104 of the companies in the S&amp;P 500 having reported. Of those, 88% have beaten consensus estimates, according to Refinitiv.</p>\n<p>Drugmaker Biogen Inc gained 1.1% after hiking its full-year revenue guidance, while Domino’s Pizza Inc surged 14.6% to an all-time high on the heels of its quarterly report.</p>\n<p>Southwest Airlines Co posted a bigger-than-expected quarterly loss, sending its stock down 3.5%, and American Airlines Group Inc dipped 1.1% even after reporting a quarterly profit.</p>\n<p>The S&amp;P 1500 Airlines index ended the session off 1.7%.</p>\n<p>Shares of Texas Instruments Inc slid 5.3% after its current-quarter revenue forecast cast concerns as to whether the company will be able to meet spiking demand in the face of a global semiconductor shortage.</p>\n<p>The Philadelphia SE Semiconductor index ended the session down 0.9%.</p>\n<p>Chipmaker Intel Corp slipped more than 1% in extended trading after the chipmaker posted results and raised its annual revenue forecast.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.82-to-1 ratio; on Nasdaq, a 1.90-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 39 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 54 new lows.</p>\n<p>Volume on U.S. exchanges was 8.25 billion shares, compared with the 10.12 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ekes out gains, led by tech, growth stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ekes out gains, led by tech, growth stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-wall-street-ekes-out-gains-led-by-tech-growth-stocks-idUSL1N2OY2HH><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-wall-street-ekes-out-gains-led-by-tech-growth-stocks-idUSL1N2OY2HH\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-wall-street-ekes-out-gains-led-by-tech-growth-stocks-idUSL1N2OY2HH","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164478982","content_text":"NEW YORK (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks.\nA pull-back in economically sensitive cyclicals kept the S&P 500’s and the blue-chip Dow’s gains muted, while small-caps underperformed their larger rivals.\nBut megacap tech and tech-adjacent stocks, such as Microsoft Corp, Amazon.com, Apple Inc, Facebook Inc and Alphabet Inc, rose ahead of their quarterly results next week, putting the Nasdaq out front.\nAll three major U.S. stock indexes ended the session within 1% of their record closing highs.\nGrowth stocks, which outperformed throughout the health crisis, were back in favor, gaining 0.8%, while the value index slipped by 0.5%.\n“The market is flip-flopping between the view that economic growth has almost peaked so you need to buy stocks that manufacture their own growth like tech names, versus the view that economic growth will continue and you want to own cyclicals and value names,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York.\nThe number of U.S. workers filing first-time applications for unemployment benefits spiked unexpectedly to 419,000 last week, a two-month high, according to the Labor Department.\nMarket participants are closely watching labor market indicators for hints as to when the Federal Reserve, expected to convene next week for its two-day monetary policy meeting, will begin discussions about hiking key interest rates from near zero.\n“The jobless data today didn’t have a meaningful impact on markets or the economic outlook,” Carter added. “It’s now all about how much longer the Fed will tolerate low rates. The Fed seems to be favoring its full employment mandate more than its price stability mandate.”\n“Accordingly, the upcoming Fed meeting could be impactful,” Carter said.\nBenchmark Treasury yields eased after the bid at the largest-ever TIPS auction touched a record low, pressuring rate sensitive banks.\nThe Dow Jones Industrial Average rose 25.35 points, or 0.07%, to 34,823.35, the S&P 500 gained 8.79 points, or 0.20%, to 4,367.48 and the Nasdaq Composite added 52.64 points, or 0.36%, to 14,684.60.\nOf the 11 major sectors of the S&P 500, tech was shining brightest, gaining 0.7%. Energy stocks suffered the largest percentage drop.\nThe second-quarter reporting season barreled ahead at full-throttle, with 104 of the companies in the S&P 500 having reported. Of those, 88% have beaten consensus estimates, according to Refinitiv.\nDrugmaker Biogen Inc gained 1.1% after hiking its full-year revenue guidance, while Domino’s Pizza Inc surged 14.6% to an all-time high on the heels of its quarterly report.\nSouthwest Airlines Co posted a bigger-than-expected quarterly loss, sending its stock down 3.5%, and American Airlines Group Inc dipped 1.1% even after reporting a quarterly profit.\nThe S&P 1500 Airlines index ended the session off 1.7%.\nShares of Texas Instruments Inc slid 5.3% after its current-quarter revenue forecast cast concerns as to whether the company will be able to meet spiking demand in the face of a global semiconductor shortage.\nThe Philadelphia SE Semiconductor index ended the session down 0.9%.\nChipmaker Intel Corp slipped more than 1% in extended trading after the chipmaker posted results and raised its annual revenue forecast.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.82-to-1 ratio; on Nasdaq, a 1.90-to-1 ratio favored decliners.\nThe S&P 500 posted 39 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 54 new lows.\nVolume on U.S. exchanges was 8.25 billion shares, compared with the 10.12 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172834932,"gmtCreate":1626950166626,"gmtModify":1633769469856,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172834932","repostId":"1124496130","repostType":4,"isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172835343,"gmtCreate":1626950110682,"gmtModify":1633769470227,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"weweew","listText":"weweew","text":"weweew","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172835343","repostId":"1137753306","repostType":4,"repost":{"id":"1137753306","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1626944539,"share":"https://www.laohu8.com/m/news/1137753306?lang=&edition=full","pubTime":"2021-07-22 17:02","market":"us","language":"en","title":"Cryptocurrency-related stocks soar in premarket trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1137753306","media":"Tiger Newspress","summary":"(July 22) Cryptocurrency-related stocks soar in premarket trading.\nBitcoin rose 1% from its 5 p.m. E","content":"<p>(July 22)&nbsp;Cryptocurrency-related stocks soar in premarket trading.</p>\n<p>Bitcoin rose 1% from its 5 p.m. ET level, trading around $32,200 and extending gains into a second day. The cryptocurrency rallied Wednesday after Tesla Chief ExecutiveElon Musksaid bothhe and his rocket company SpaceX hold bitcoin.</p>\n<p><img src=\"https://static.tigerbbs.com/72881d44f1f43108ff16826114112776\" tg-width=\"301\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cryptocurrency-related stocks soar in premarket trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCryptocurrency-related stocks soar in premarket trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-22 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(July 22)&nbsp;Cryptocurrency-related stocks soar in premarket trading.</p>\n<p>Bitcoin rose 1% from its 5 p.m. ET level, trading around $32,200 and extending gains into a second day. The cryptocurrency rallied Wednesday after Tesla Chief ExecutiveElon Musksaid bothhe and his rocket company SpaceX hold bitcoin.</p>\n<p><img src=\"https://static.tigerbbs.com/72881d44f1f43108ff16826114112776\" tg-width=\"301\" tg-height=\"324\" referrerpolicy=\"no-referrer\"></p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137753306","content_text":"(July 22) Cryptocurrency-related stocks soar in premarket trading.\nBitcoin rose 1% from its 5 p.m. ET level, trading around $32,200 and extending gains into a second day. The cryptocurrency rallied Wednesday after Tesla Chief ExecutiveElon Musksaid bothhe and his rocket company SpaceX hold bitcoin.","news_type":1},"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":176884606,"gmtCreate":1626876300205,"gmtModify":1633770195986,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"wow like","listText":"wow like","text":"wow like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/176884606","repostId":"1139204971","repostType":4,"repost":{"id":"1139204971","kind":"news","pubTimestamp":1626873342,"share":"https://www.laohu8.com/m/news/1139204971?lang=&edition=full","pubTime":"2021-07-21 21:15","market":"us","language":"en","title":"Chembio Shares Double on $28 Million COVID Diagnostic Test Order","url":"https://stock-news.laohu8.com/highlight/detail?id=1139204971","media":"The Street","summary":"Chembio will provide 20-minute nasal swab test to a company in Brazil.\n\nShares of Chembio Diagnostic","content":"<blockquote>\n Chembio will provide 20-minute nasal swab test to a company in Brazil.\n</blockquote>\n<p>Shares of <a href=\"https://laohu8.com/S/CEMI\">Chembio Diagnostics</a>&nbsp;(<b>CEMI</b>) -Get Report&nbsp;doubled in premarket trading Wednesday after the company received a $28.3 million purchase order from Bio-Manguinhos for SARS-CoV-2 Antigen tests in Brazil.</p>\n<p>The test is designed to detect the COVID-19 pathogen in only 20 minutes using a \"minimally invasive\" nasal swab.</p>\n<p>“We are pleased to significantly expand our customer relationship with Bio-Manguinhos to address the testing needs surrounding COVID-19,” said Javan Esfandiari, Chembio’s executive vice president, chief science and technology officer.</p>\n<p>Shares of Chembio Diagnostics jumped 100.49% to $4.13 early Wednesday.</p>\n<p>\"We believe the purchase order validates the investments we made earlier this year in inventory for the DPP SARS-CoV-2 Antigen test and look forward to ramping up production,\" Esfandiari said.</p>\n<p>Chembio is a point-of-care diagnostic company focused on infectious diseases.</p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chembio Shares Double on $28 Million COVID Diagnostic Test Order</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChembio Shares Double on $28 Million COVID Diagnostic Test Order\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-21 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/chembio-diagnostics-cemi-covid-test-order><strong>The Street</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chembio will provide 20-minute nasal swab test to a company in Brazil.\n\nShares of Chembio Diagnostics (CEMI) -Get Report doubled in premarket trading Wednesday after the company received a $28.3 ...</p>\n\n<a href=\"https://www.thestreet.com/investing/chembio-diagnostics-cemi-covid-test-order\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CEMI":"Chembio Diagnostics"},"source_url":"https://www.thestreet.com/investing/chembio-diagnostics-cemi-covid-test-order","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1139204971","content_text":"Chembio will provide 20-minute nasal swab test to a company in Brazil.\n\nShares of Chembio Diagnostics (CEMI) -Get Report doubled in premarket trading Wednesday after the company received a $28.3 million purchase order from Bio-Manguinhos for SARS-CoV-2 Antigen tests in Brazil.\nThe test is designed to detect the COVID-19 pathogen in only 20 minutes using a \"minimally invasive\" nasal swab.\n“We are pleased to significantly expand our customer relationship with Bio-Manguinhos to address the testing needs surrounding COVID-19,” said Javan Esfandiari, Chembio’s executive vice president, chief science and technology officer.\nShares of Chembio Diagnostics jumped 100.49% to $4.13 early Wednesday.\n\"We believe the purchase order validates the investments we made earlier this year in inventory for the DPP SARS-CoV-2 Antigen test and look forward to ramping up production,\" Esfandiari said.\nChembio is a point-of-care diagnostic company focused on infectious diseases.","news_type":1},"isVote":1,"tweetType":1,"viewCount":158,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":173584291,"gmtCreate":1626670334213,"gmtModify":1633925045752,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577522329316309","authorIdStr":"3577522329316309"},"themes":[],"htmlText":"likey","listText":"likey","text":"likey","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/173584291","repostId":"1131628595","repostType":4,"repost":{"id":"1131628595","kind":"news","pubTimestamp":1626665643,"share":"https://www.laohu8.com/m/news/1131628595?lang=&edition=full","pubTime":"2021-07-19 11:34","market":"us","language":"en","title":"Investors are very scared even with stocks near record highs","url":"https://stock-news.laohu8.com/highlight/detail?id=1131628595","media":"CNN","summary":"New York The Dow and S&P 500 are both up about 15% in 2021 and are each about a percent away from their all-time highs. But as Friday's market sell-off showed, investors remain extremely nervous about the market.The CNN Business Fear & Greed Index, which looks at seven different measures of market sentiment, is showing signs of Extreme Fear. Four of the seven indicators are in bearish territory.Demand for safe haven bonds is picking up. That's pushed the benchmark 10-year Treasury yield all the ","content":"<p>New York (CNN Business)The Dow and S&amp;P 500 are both up about 15% in 2021 and are each about a percent away from their all-time highs. But as Friday's market sell-off showed, investors remain extremely nervous about the market.</p>\n<p>The CNN Business Fear &amp; Greed Index, which looks at seven different measures of market sentiment, is showing signs of Extreme Fear. Four of the seven indicators are in bearish territory.</p>\n<p>Demand for safe haven bonds is picking up. That's pushed the benchmark 10-year Treasury yield all the way down to 1.3%, compared to a level above 1.75% as recently as March.</p>\n<p>Investors are also buying more put options, contracts that give them the right to sell stocks and other assets at a specific price.</p>\n<p>The number of companies with stocks hitting new 52-week lows versus highs is increasing, and trading volume for stocks that are falling is also outpacing volume for stocks that are climbing. But the solid gains for the FAANGs of Big Tech have helped lift the broader market in spite of this.</p>\n<p>A little bit of fear is healthy</p>\n<p>There are several legitimate reasons for investors to be worried.</p>\n<p>Even though the economy and corporate earnings have rebounded sharply from their pandemic era lows of last spring and early summer, worries persist about the Delta variant and the fact that many Americans remain unvaccinated.</p>\n<p>There are also conflicting signs about the recovery. The US government reported a sharp rebound in retail sales for June on Friday but that was complicated by another report showing a sizable drop in consumer confidence.</p>\n<p>The persistent rise in the prices of many consumer goods is raising inflation alarm bells as well.</p>\n<p>Still, some market experts believe that the skepticism is healthy.</p>\n<p>There's a saying on Wall Street that stocks climb a wall of worry, meaning that it's a good sign if the market is going up even though there are legitimate concerns. The absence of such worry can often lead to excessive speculation and market bubbles.</p>\n<p>\"It's not abnormal after you have a jolt in the economy and market to have lingering fear. It takes a long time for investors to become comfortable with advances in stocks coming off the bottom,\" said Kelly Bogdanova, vice president of the portfolio advisory group with RBC Wealth Management.</p>\n<p>\"I'd rather see some fear than people being complacent. Investors being nervous doesn't trouble me,\" she added.</p>\n<p>Bumpier ride for stocks but path of least resistance is up</p>\n<p>That being said, investors may have to brace themselves for more volatility in the coming months.</p>\n<p>The so-called easy money in stocks may have already been made during this year's stock surge. Bogdanova said that \"the market is now entering a transition period\" and instead of \"explosive growth, it will be a two steps forward and one step back\" type of environment.</p>\n<p>Inflation concerns and skittishness about how the Federal Reserve will react to headlines about higher prices are likely to stick around too. But the recent slide in bond yields might actually be an encouraging sign for investors.</p>\n<p>If the bond market was really that afraid of inflation, yields would be rising instead of falling. Inflation typically leads to much higher interest rates, not the other way around.</p>\n<p>So it would appear that bond investors agree with Fed chair Jerome Powell, who has repeatedly described the current bout of inflation as \"transitory.\"</p>\n<p>\"The bond market is giving the message that inflation concerns are not permanent,\" said Steve Wyett, chief investment strategist with BOK Financial.</p>\n<p>There's also the fact that corporate earnings are expected to keep climbing. That bodes well for stocks.</p>\n<p>According to FactSet, analysts expect corporate profits to rise 24% from a year ago in the third quarter and increase nearly 19% in the fourth quarter. Growth is expected to dip somewhat next year, but analysts are still forecasting a healthy 11% increase in earnings for 2022.</p>\n<p>What's more, profits are climbing even as many companies are raising wages to entice people back into the work force.</p>\n<p>\"There is room for companies to pay more for labor and not hurt their margins,\" Wyett said. \"We should see continued earnings growth. The stage is set to go from a stimulus led recovery to one with private sector expansion.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors are very scared even with stocks near record highs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors are very scared even with stocks near record highs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-19 11:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/07/17/investing/stocks-fear-greed/index.html><strong>CNN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York (CNN Business)The Dow and S&P 500 are both up about 15% in 2021 and are each about a percent away from their all-time highs. But as Friday's market sell-off showed, investors remain extremely...</p>\n\n<a href=\"https://edition.cnn.com/2021/07/17/investing/stocks-fear-greed/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://edition.cnn.com/2021/07/17/investing/stocks-fear-greed/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1131628595","content_text":"New York (CNN Business)The Dow and S&P 500 are both up about 15% in 2021 and are each about a percent away from their all-time highs. But as Friday's market sell-off showed, investors remain extremely nervous about the market.\nThe CNN Business Fear & Greed Index, which looks at seven different measures of market sentiment, is showing signs of Extreme Fear. Four of the seven indicators are in bearish territory.\nDemand for safe haven bonds is picking up. That's pushed the benchmark 10-year Treasury yield all the way down to 1.3%, compared to a level above 1.75% as recently as March.\nInvestors are also buying more put options, contracts that give them the right to sell stocks and other assets at a specific price.\nThe number of companies with stocks hitting new 52-week lows versus highs is increasing, and trading volume for stocks that are falling is also outpacing volume for stocks that are climbing. But the solid gains for the FAANGs of Big Tech have helped lift the broader market in spite of this.\nA little bit of fear is healthy\nThere are several legitimate reasons for investors to be worried.\nEven though the economy and corporate earnings have rebounded sharply from their pandemic era lows of last spring and early summer, worries persist about the Delta variant and the fact that many Americans remain unvaccinated.\nThere are also conflicting signs about the recovery. The US government reported a sharp rebound in retail sales for June on Friday but that was complicated by another report showing a sizable drop in consumer confidence.\nThe persistent rise in the prices of many consumer goods is raising inflation alarm bells as well.\nStill, some market experts believe that the skepticism is healthy.\nThere's a saying on Wall Street that stocks climb a wall of worry, meaning that it's a good sign if the market is going up even though there are legitimate concerns. The absence of such worry can often lead to excessive speculation and market bubbles.\n\"It's not abnormal after you have a jolt in the economy and market to have lingering fear. It takes a long time for investors to become comfortable with advances in stocks coming off the bottom,\" said Kelly Bogdanova, vice president of the portfolio advisory group with RBC Wealth Management.\n\"I'd rather see some fear than people being complacent. Investors being nervous doesn't trouble me,\" she added.\nBumpier ride for stocks but path of least resistance is up\nThat being said, investors may have to brace themselves for more volatility in the coming months.\nThe so-called easy money in stocks may have already been made during this year's stock surge. Bogdanova said that \"the market is now entering a transition period\" and instead of \"explosive growth, it will be a two steps forward and one step back\" type of environment.\nInflation concerns and skittishness about how the Federal Reserve will react to headlines about higher prices are likely to stick around too. But the recent slide in bond yields might actually be an encouraging sign for investors.\nIf the bond market was really that afraid of inflation, yields would be rising instead of falling. Inflation typically leads to much higher interest rates, not the other way around.\nSo it would appear that bond investors agree with Fed chair Jerome Powell, who has repeatedly described the current bout of inflation as \"transitory.\"\n\"The bond market is giving the message that inflation concerns are not permanent,\" said Steve Wyett, chief investment strategist with BOK Financial.\nThere's also the fact that corporate earnings are expected to keep climbing. That bodes well for stocks.\nAccording to FactSet, analysts expect corporate profits to rise 24% from a year ago in the third quarter and increase nearly 19% in the fourth quarter. Growth is expected to dip somewhat next year, but analysts are still forecasting a healthy 11% increase in earnings for 2022.\nWhat's more, profits are climbing even as many companies are raising wages to entice people back into the work force.\n\"There is room for companies to pay more for labor and not hurt their margins,\" Wyett said. \"We should see continued earnings growth. The stage is set to go from a stimulus led recovery to one with private sector expansion.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":173,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":174816401,"gmtCreate":1627090252103,"gmtModify":1633768108101,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/174816401","repostId":"2153980423","repostType":4,"repost":{"id":"2153980423","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1627081209,"share":"https://www.laohu8.com/m/news/2153980423?lang=&edition=full","pubTime":"2021-07-24 07:00","market":"us","language":"en","title":"Wall Street surges to all-time closing high on earnings, economic revival","url":"https://stock-news.laohu8.com/highlight/detail?id=2153980423","media":"Reuters","summary":"* All 3 major indexes post weekly gains\n* Dow closes above 35,000 for first time ever\n* Social media","content":"<p>* All 3 major indexes post weekly gains</p>\n<p>* Dow closes above 35,000 for first time ever</p>\n<p>* Social media stocks rally after upbeat results</p>\n<p>* Intel sales forecast implies rocky second half</p>\n<p>* Indexes up: Dow 0.68%, S&amp;P 1.01%, Nasdaq 1.04%</p>\n<p>Wall Street gained ground for the fourth straight session on Friday, extending a rally that pushed all three major U.S. stock indexes to record closing highs as upbeat earnings and signs of economic revival fueled investor risk appetite.</p>\n<p>The Dow closed above 35,000 for the first time ever.</p>\n<p>\"We see a continuation of the last couple days. It's roller coaster in reverse. We did the drop first, and we’ve been climbing back to the top ever since,\" said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.</p>\n<p>Growth and value stocks seesawed for much of the week as market participants weighed spiking infections of the COVID-19 Delta variant against strong corporate results and signs of economic revival.</p>\n<p>\"There’s push and pull, there’s clearly conflict in the market,\" Zaccarelli added. \"There’s a strong difference of opinion as to whether the future’s bright or whether there are clouds on the horizon.\"</p>\n<p>Market participants now look toward next week with the Federal Reserve's two-day monetary policy meeting and a series of high-profile earnings.</p>\n<p>The Fed's statement will be parsed for clues regarding the timeframe for tightening its accommodative policies, although Chairman Jerome Powell has repeatedly said the economy still needs the central bank's full support.</p>\n<p>The Dow Jones Industrial Average rose 238.2 points, or 0.68%, to 35,061.55, the S&amp;P 500 gained 44.31 points, or 1.01%, to 4,411.79 and the Nasdaq Composite added 152.39 points, or 1.04%, to 14,836.99.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but energy&nbsp;closed green, with communications services enjoying the largest gain, rising 2.7%.</p>\n<p>Second-quarter reporting season is in full swing, with 120 of the companies in the S&amp;P 500 having reported. Of those, 88% have beaten consensus, according to Refinitiv.</p>\n<p>\"We’re seeing companies, on average, beat on the top and on the bottom line,\" Zaccarelli said. \"We’re seeing the resilience of the consumer and that’s been the story of the earnings season so far.\"</p>\n<p>Analysts now expect aggregate year-on-year S&amp;P 500 earnings growth of 78.1% for the April to June period, a sizeable increase from the 54% annual growth seen at the beginning of the quarter.</p>\n<p>Chipmaker Intel Corp said late Thursday that it still faces supply constraints and provided disappointing guidance. Its stock fell 5.3%.</p>\n<p>Moderna Inc jumped 7.8% after the European Union approved its COVID-19 vaccine for 12- to 17-year-olds.</p>\n<p>American <a href=\"https://laohu8.com/S/EXPR\">Express</a> Co gained 1.3% after posting second-quarter profit that handily beat expectations on the strength of a global recovery in consumer spending.</p>\n<p>Social media firms <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> Inc and <a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>&nbsp;advanced 3.0% and 23.8%, respectively, on the back of their upbeat results.</p>\n<p>Those results bode well for <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, which is due to post second-quarter results next week. Its stock surged 5.3%.</p>\n<p>Other high-profile earnings expected next week include Tesla Inc, Apple Inc, Alphabet Inc, Microsoft Corp and Amazon.com.</p>\n<p>Industrials Lockheed Martin Corp, Boeing Co, Ford Motor Co, General Dynamics Corp, <a href=\"https://laohu8.com/S/MMM\">3M</a> Co Caterpillar Inc, Chevron Corp and Exxon Mobil Corp, along with a host of healthcare, consumer goods and others, are also on deck.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.59-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 82 new 52-week highs and no new lows; the Nasdaq Composite recorded 81 new highs and 136 new lows.</p>\n<p>Volume on U.S. exchanges was 9.72 billion shares, compared with the 10.14 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street surges to all-time closing high on earnings, economic revival</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street surges to all-time closing high on earnings, economic revival\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-24 07:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>* All 3 major indexes post weekly gains</p>\n<p>* Dow closes above 35,000 for first time ever</p>\n<p>* Social media stocks rally after upbeat results</p>\n<p>* Intel sales forecast implies rocky second half</p>\n<p>* Indexes up: Dow 0.68%, S&amp;P 1.01%, Nasdaq 1.04%</p>\n<p>Wall Street gained ground for the fourth straight session on Friday, extending a rally that pushed all three major U.S. stock indexes to record closing highs as upbeat earnings and signs of economic revival fueled investor risk appetite.</p>\n<p>The Dow closed above 35,000 for the first time ever.</p>\n<p>\"We see a continuation of the last couple days. It's roller coaster in reverse. We did the drop first, and we’ve been climbing back to the top ever since,\" said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.</p>\n<p>Growth and value stocks seesawed for much of the week as market participants weighed spiking infections of the COVID-19 Delta variant against strong corporate results and signs of economic revival.</p>\n<p>\"There’s push and pull, there’s clearly conflict in the market,\" Zaccarelli added. \"There’s a strong difference of opinion as to whether the future’s bright or whether there are clouds on the horizon.\"</p>\n<p>Market participants now look toward next week with the Federal Reserve's two-day monetary policy meeting and a series of high-profile earnings.</p>\n<p>The Fed's statement will be parsed for clues regarding the timeframe for tightening its accommodative policies, although Chairman Jerome Powell has repeatedly said the economy still needs the central bank's full support.</p>\n<p>The Dow Jones Industrial Average rose 238.2 points, or 0.68%, to 35,061.55, the S&amp;P 500 gained 44.31 points, or 1.01%, to 4,411.79 and the Nasdaq Composite added 152.39 points, or 1.04%, to 14,836.99.</p>\n<p>Of the 11 major sectors in the S&amp;P 500, all but energy&nbsp;closed green, with communications services enjoying the largest gain, rising 2.7%.</p>\n<p>Second-quarter reporting season is in full swing, with 120 of the companies in the S&amp;P 500 having reported. Of those, 88% have beaten consensus, according to Refinitiv.</p>\n<p>\"We’re seeing companies, on average, beat on the top and on the bottom line,\" Zaccarelli said. \"We’re seeing the resilience of the consumer and that’s been the story of the earnings season so far.\"</p>\n<p>Analysts now expect aggregate year-on-year S&amp;P 500 earnings growth of 78.1% for the April to June period, a sizeable increase from the 54% annual growth seen at the beginning of the quarter.</p>\n<p>Chipmaker Intel Corp said late Thursday that it still faces supply constraints and provided disappointing guidance. Its stock fell 5.3%.</p>\n<p>Moderna Inc jumped 7.8% after the European Union approved its COVID-19 vaccine for 12- to 17-year-olds.</p>\n<p>American <a href=\"https://laohu8.com/S/EXPR\">Express</a> Co gained 1.3% after posting second-quarter profit that handily beat expectations on the strength of a global recovery in consumer spending.</p>\n<p>Social media firms <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> Inc and <a href=\"https://laohu8.com/S/SNAP\">Snap Inc</a>&nbsp;advanced 3.0% and 23.8%, respectively, on the back of their upbeat results.</p>\n<p>Those results bode well for <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc, which is due to post second-quarter results next week. Its stock surged 5.3%.</p>\n<p>Other high-profile earnings expected next week include Tesla Inc, Apple Inc, Alphabet Inc, Microsoft Corp and Amazon.com.</p>\n<p>Industrials Lockheed Martin Corp, Boeing Co, Ford Motor Co, General Dynamics Corp, <a href=\"https://laohu8.com/S/MMM\">3M</a> Co Caterpillar Inc, Chevron Corp and Exxon Mobil Corp, along with a host of healthcare, consumer goods and others, are also on deck.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.59-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 82 new 52-week highs and no new lows; the Nasdaq Composite recorded 81 new highs and 136 new lows.</p>\n<p>Volume on U.S. exchanges was 9.72 billion shares, compared with the 10.14 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EXPR":"Express, Inc.",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","SNAP":"Snap Inc",".SPX":"S&P 500 Index","TWTR":"Twitter"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153980423","content_text":"* All 3 major indexes post weekly gains\n* Dow closes above 35,000 for first time ever\n* Social media stocks rally after upbeat results\n* Intel sales forecast implies rocky second half\n* Indexes up: Dow 0.68%, S&P 1.01%, Nasdaq 1.04%\nWall Street gained ground for the fourth straight session on Friday, extending a rally that pushed all three major U.S. stock indexes to record closing highs as upbeat earnings and signs of economic revival fueled investor risk appetite.\nThe Dow closed above 35,000 for the first time ever.\n\"We see a continuation of the last couple days. It's roller coaster in reverse. We did the drop first, and we’ve been climbing back to the top ever since,\" said Chris Zaccarelli, chief investment officer at Independent Advisor Alliance in Charlotte, North Carolina.\nGrowth and value stocks seesawed for much of the week as market participants weighed spiking infections of the COVID-19 Delta variant against strong corporate results and signs of economic revival.\n\"There’s push and pull, there’s clearly conflict in the market,\" Zaccarelli added. \"There’s a strong difference of opinion as to whether the future’s bright or whether there are clouds on the horizon.\"\nMarket participants now look toward next week with the Federal Reserve's two-day monetary policy meeting and a series of high-profile earnings.\nThe Fed's statement will be parsed for clues regarding the timeframe for tightening its accommodative policies, although Chairman Jerome Powell has repeatedly said the economy still needs the central bank's full support.\nThe Dow Jones Industrial Average rose 238.2 points, or 0.68%, to 35,061.55, the S&P 500 gained 44.31 points, or 1.01%, to 4,411.79 and the Nasdaq Composite added 152.39 points, or 1.04%, to 14,836.99.\nOf the 11 major sectors in the S&P 500, all but energy closed green, with communications services enjoying the largest gain, rising 2.7%.\nSecond-quarter reporting season is in full swing, with 120 of the companies in the S&P 500 having reported. Of those, 88% have beaten consensus, according to Refinitiv.\n\"We’re seeing companies, on average, beat on the top and on the bottom line,\" Zaccarelli said. \"We’re seeing the resilience of the consumer and that’s been the story of the earnings season so far.\"\nAnalysts now expect aggregate year-on-year S&P 500 earnings growth of 78.1% for the April to June period, a sizeable increase from the 54% annual growth seen at the beginning of the quarter.\nChipmaker Intel Corp said late Thursday that it still faces supply constraints and provided disappointing guidance. Its stock fell 5.3%.\nModerna Inc jumped 7.8% after the European Union approved its COVID-19 vaccine for 12- to 17-year-olds.\nAmerican Express Co gained 1.3% after posting second-quarter profit that handily beat expectations on the strength of a global recovery in consumer spending.\nSocial media firms Twitter Inc and Snap Inc advanced 3.0% and 23.8%, respectively, on the back of their upbeat results.\nThose results bode well for Facebook Inc, which is due to post second-quarter results next week. Its stock surged 5.3%.\nOther high-profile earnings expected next week include Tesla Inc, Apple Inc, Alphabet Inc, Microsoft Corp and Amazon.com.\nIndustrials Lockheed Martin Corp, Boeing Co, Ford Motor Co, General Dynamics Corp, 3M Co Caterpillar Inc, Chevron Corp and Exxon Mobil Corp, along with a host of healthcare, consumer goods and others, are also on deck.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.59-to-1 ratio; on Nasdaq, a 1.03-to-1 ratio favored advancers.\nThe S&P 500 posted 82 new 52-week highs and no new lows; the Nasdaq Composite recorded 81 new highs and 136 new lows.\nVolume on U.S. exchanges was 9.72 billion shares, compared with the 10.14 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":151936908,"gmtCreate":1625061239004,"gmtModify":1633945327088,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"oo","listText":"oo","text":"oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/151936908","repostId":"1150186389","repostType":4,"repost":{"id":"1150186389","kind":"news","pubTimestamp":1625044819,"share":"https://www.laohu8.com/m/news/1150186389?lang=&edition=full","pubTime":"2021-06-30 17:20","market":"us","language":"en","title":"Which of the 10 Most Talked About Reddit Stocks Is Worth a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=1150186389","media":"InvestorPlace","summary":"Like all investments, there are good Reddit stocks, and bad ones\nSource: Marcus Krauss / Shutterstoc","content":"<p>Like all investments, there are good Reddit stocks, and bad ones</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/753e957cac964de085fbdea1b1aa30a1\" tg-width=\"1024\" tg-height=\"576\"><span>Source: Marcus Krauss / Shutterstock.com</span></p>\n<p>I must admit, when I was given this assignment my first thought was I’m the last guy to be talking about Reddit stocks. I think the attention being paid to Reddit and meme stocks is a bunch of hokum.</p>\n<p>The arguments abound whether the meme stock frenzy is&nbsp;a permanent part of the investing landscape.</p>\n<p>“This is not going to end well,” Former E*Trade CEO Karl Roessner told<i>CNBC</i>in early June while discussing the AMC rally. “I think historically we’ve seen this in the past, but I do believethis grouphas staying power.”</p>\n<p>However, if you’re a value investor, the mere presence of this kind of retail investor is music to your ears. While the sheep are out buying&nbsp;<b>GameStop</b>(NYSE:<b><u>GME</u></b>), you can pick up shares in some of America’s better companies that trade at a discount.</p>\n<p>That’s not easy when the&nbsp;Cyclically Adjusted PE Ratio&nbsp;(CAPE) of 38.11 is at the second-highest level on record — the highest was in December 1999 — with no end in sight to the multiple’s upward trajectory.</p>\n<p>With that in mind, I’ve rated the&nbsp;top 10 Reddit stocks— based on the number of comments made on r/WallStreetBets — from best to worst as a long-term buy:</p>\n<ul>\n <li><b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>)</li>\n <li><b>KB Home</b>(NYSE:<b><u>KBH</u></b>)</li>\n <li><b>Palantir Technologies</b>(NYSE:<b><u>PLTR</u></b>)</li>\n <li><b>Clean Energy Fuels</b>(NASDAQ:<b><u>CLNE</u></b>)</li>\n <li><b>BlackBerry</b>(NYSE:<b><u>BB</u></b>)</li>\n <li><b>Workhorse Group</b>(NASDAQ:<b><u>WKHS</u></b>)</li>\n <li><b>AMC Entertainment</b>(NYSE:<b><u>AMC</u></b>)</li>\n <li><b>ContextLogic</b>(NASDAQ:<b><u>WISH</u></b>)</li>\n <li><b>Globalstar</b>(NYSEAMERICAN:<b><u>GSAT</u></b>)</li>\n <li><b>Clover Health</b>(NASDAQ:<b><u>CLOV</u></b>)</li>\n</ul>\n<p><b>Tesla (TSLA)</b></p>\n<p>Say what you will about Elon Musk, but there’s no question he’s built one heck of a company. Soon, Tesla will have a fourth factory open in Berlin. Even though the original opening date of July 1 is no longer on the table due to myriad reasons, it will ultimately produce millions of electric vehicles (EVs) for willing European buyers.</p>\n<p>The company has added a&nbsp;battery cell production&nbsp;component to the plant outside Berlin. It will produce 500 million cells annually representing 50 gigawatt hours (GWh) of energy, 25% higher than&nbsp;<b>Volkswagen’s</b>(OTCMKTS:<b><u>VWAGY</u></b>) planned facility a couple hundred miles away.</p>\n<p>Across the pond in Texas, the company’s fifth so-called Gigafactory is getting closer to being ready for production. This plant will produce an updated version of the Model Y using “mega casting” technology to speed up the production process while delivering a lighter vehicle at the same time. It currently&nbsp;uses this technology&nbsp;at its plant in Shanghai.</p>\n<p>Tesla has afree cash flow (FCF) marginof 22.3% based on $35.94 billion in trailing-12-month revenue.</p>\n<p><b>KB Home (KBH)</b></p>\n<p>The largest homebuilders in America are having&nbsp;trouble keeping up with demand&nbsp;at the moment. At least for now, KB Home is meeting the demand from customers, 64% of which were first-time buyers in the latest quarter.</p>\n<p>“Operationally, our divisions are doing an&nbsp;excellent job&nbsp;of navigating this environment of demand strength and well-publicized supply chain constraints as we effectively balanced pace, price and starts to optimize our assets and manage our production,” said KB Home CEO Jeff Mezger in the Q2 2021 conference call.</p>\n<p>KB Home is so busy that the number of homes started in Q1 2021 and Q2 2021 was equivalent to 75% of the number of homes started for 2020. As a result, it expects to deliver $6 billion in housing revenue in 2021 at the midpoint of guidance, with operating margins between 11.5% and 12.0%.</p>\n<p>KB Home has anFCF margin of 6.5%based on $4.78 billion in trailing 12-month revenue.</p>\n<p><b>Palantir Technologies (PLTR)</b></p>\n<p>Palantir has been a public company for less than a year. The provider of data analytics software platforms for government agencies, corporations, and other large institutions, sold no shares last September when directly listedon the NYSE.</p>\n<p>The reference price was $7.25. PLTR stock is up 277.7% through the start of June 29.</p>\n<p>Not only is it growing its business — in the latest quarter, itsU.S. commercial revenuegrew 72% year-over-year while its U.S. government revenue jumped 83% YOY — it is also busy investing in other tech companies looking to go public.</p>\n<p>For example, it has invested in six private investments in public equity (PIPE) in the past three months. These PIPEs are part of the ongoing interest in special purpose acquisition companies (SPACs). Palantir invests&nbsp;in the PIPEs&nbsp;to gain financial returns and collaborate with these companies, which use its data analytic tools for their businesses.</p>\n<p>I’m not 100% sold on Palantir&nbsp;just yet, but it’s a good long-term buy compared to some of the Reddit stocks on this list.</p>\n<p>Palantir has anFCF margin of 9%based on $1.2 billion in trailing 12-month revenue.</p>\n<p><b>Clean Energy Fuels</b><b>(</b><b>CLNE)</b></p>\n<p>Back in February,I recommended CLNE. At the time, it was trading around $12.97. It was one of seven stocks to buy under $20. As I write this, it’s just under $11, so it’s lost ground over the past four months.</p>\n<p>I liked Clean Energy for several reasons.</p>\n<p>First, it provides three kinds of natural gas fuel for commercial trucks: compressed (CNG), liquified (LNG), and renewable (RNG). It’s the only fuel provider to do so. Secondly, RNG fuel enables trucking companies to deliver their services while getting close to or achieving carbon negative status. Third, it’s got fueling stations in 43 states and Canada. Lastly, it’s got deep pockets.<b>Total</b>(OTCMKTS:<b><u>TTFNF</u></b>) owns 25% of its stock.</p>\n<p>Oh, and as I said in February, from an adjusted EBITDA basis (earnings before interest, taxes, depreciation and amortization), it makes money while also growing revenues at a steady pace.</p>\n<p>In the meantime, Clean Energy has anFCF margin of 24.2%based on $283 million in trailing 12-month revenue.</p>\n<p><b>BlackBerry (BB)</b></p>\n<p>I can remember when&nbsp;President Barack Obama&nbsp;first entered the White House in January 2009. The BlackBerry was considered the cat’s meow when it came to mobile phones. By the time he left office in January 2017, it was in the dustbin of history.</p>\n<p>Now supplying security software to automobile manufacturers and other enterprises and governments worldwide — a research firm recently said its QNX software is installed in195 million vehicles&nbsp;worldwide — the Reddit crowd have taken to the Waterloo, Ontario-based tech company.</p>\n<p>Things have turned around for BlackBerry.</p>\n<p>At least, enough so to provide CEO John Chen with a handsome compensation package. Proxy advisory firm Glass Lewis recently blasted the company, suggesting its&nbsp;compensation plan&nbsp;had no relation to its overall corporate performance.</p>\n<p>As a result of the January Reddit rally, which saw BB stock move from $6.70 at the beginning of the month to a 52-week high of $28.77 by the end, Chen could receive as much as $206 million in cash and stock compensation from the long-term incentives issued in 2019.</p>\n<p>On a GAAP basis,BlackBerry still loses money. That said, the pivot it’s made to software has given it another shot at tech stardom. We’ll see if it gain regain its former glory from the Obama years.</p>\n<p>In the meantime, BlackBerry has anFCF margin of 9.3%based on $861 million in trailing 12-month revenue.</p>\n<p><b>Workhorse Group (WKHS)</b></p>\n<p>The last time I wrote about Workhorse Group was in late April. At the time, it was trading around $12.50. I argued that if it got the&nbsp;backlog of 8,000&nbsp;commercial electric vehicle delivery trucks out the door over the next 12 to 24 months, it would have an ultra-low price-to-sales ratio of 4.2.</p>\n<p>Long story short, if it did, its stock would be worth more than $12.50.</p>\n<p>Well, on June 16, Workhorse&nbsp;officially protested&nbsp;the United States Postal Service awarding the estimated $6 billion contract to manufacture its next-generation delivery vehicle to&nbsp;<b>Oshkosh</b>(NYSE:<b><u>OSK</u></b>). The news pushed WKHS to $17.54 at the start of June 29.</p>\n<p><i>InvestorPlace’s</i>&nbsp;Dana Blankenhorn recently discussed Workhorse. He believes that the company was in the commercial EV game to&nbsp;ride on the coattails&nbsp;of big guns like&nbsp;<b>Ford</b>(NYSE:<b><u>F</u></b>) and&nbsp;<b>General Motors</b>(NYSE:<b><u>GM</u></b>). That’s not the craziest theory in the world.</p>\n<p>In the latest quarter, Workhorse delivered six trucks to customers and generated $521,000 in revenue. It plans to produce&nbsp;1,000 trucks&nbsp;in 2021. It will have to pick up the pace if it wants to reach that goal. In the meantime, investors can expect its quarterly losses to accelerate as we make our way through the year.</p>\n<p>Workhorse has an&nbsp;FCF margin of -5,320.2%&nbsp;based on $1.83 million in trailing 12-month revenue. It is for speculative investors only.</p>\n<p><b>AMC Entertainment (AMC)</b></p>\n<p>AMC is a stock that I’m conflicted about.</p>\n<p>On the one hand, I believe that Americans will return to movie theaters in large numbers come fall. That will likely return the chain to pre-Covid revenue numbers. On the other hand, it has a burdensome debt load.</p>\n<p>Despite using the Reddit surge to raise much-needed cash to repay some of this debt — on June 3, it announced it would sell 11.55 million shares at the market to bring in another&nbsp;$600 million— it still has&nbsp;$11.05 billion&nbsp;owed, or 37.6% of its vastly overvalued market capitalization of $29.4 billion.</p>\n<p>Former E*Trade CEO Karl Roessner appeared on&nbsp;<i>CNBC</i>&nbsp;in early June. While he&nbsp;commended AMC management&nbsp;for selling shares when prices were high, the company is not worth $28 billion.</p>\n<p>“Absent some serious strategic undertakings by that company, it’s still just not worth what it’s trading for right now,” Roessner stated.</p>\n<p>I couldn’t agree more.</p>\n<p>AMC has anFCF margin of -280%based on $449 million in trailing 12-month revenue.</p>\n<p><b>ContextLogic (WISH)</b></p>\n<p>In February, I wrote an article about the e-commerce site with the headline“ContextLogic Has Nothing to Do With Retail”<i>.</i>I didn’t understand the composition of its board. It had no retail experience on its board to oversee the CEO.</p>\n<p>“If ContextLogic’s goal is to beat&nbsp;<b>Amazon</b>(NASDAQ:<b>AMZN</b>) at discount e-commerce apparel, its board of directors is a sure sign that’s not what it’s after,” I said.</p>\n<p>I finished the article by stating I didn’t get an inspirational vibe from Context Logic’s board of directors. In the four months since, WISH has lost 49% of its value and trades well below its&nbsp;IPO price&nbsp;of $24.</p>\n<p>ContextLogic has anFCF margin of -8%based on $2.87 billion in trailing 12-month revenue. I’m really not sure what Redditors see in this one.</p>\n<p><b>Globalstar (GSAT)</b></p>\n<p>Not everyone thinks the provider of mobile satellite services is a bad bet.</p>\n<p>B. Riley analyst Mike Crawford initiated coverage of Globalstar on June 21. The analyst gives it a “buy” rating and a&nbsp;$3.25 target price, double where it’s currently trading. He estimates that the company’s C-Band spectrum could be worth as much as $15 billion. Based on 1.79 billion shares outstanding, that’s $8.38 a share, considerably higher than the analyst’s target price.</p>\n<p>From where I sit, the fact that it’s currently trading at&nbsp;a price-to-sales ratio of 25.39&nbsp;and&nbsp;not making money&nbsp;on a GAAP basis makes it very hard for me to get behind the company.</p>\n<p>However, Globalstar does have one big ace up its sleeve.</p>\n<p>On page 87 of its&nbsp;2020 10-K, you will see that it had $1.8 billion in U.S. net operating loss (NOL) carryforwards with less than 1% expiring before 2025. It has an additional $200 million in foreign NOL carryforwards. So, should it start generating significant profits — that’s still very much up in the air — the loss carryforwards will shield the company’s earnings from taxes for the foreseeable future.</p>\n<p>Globalstar has anFCF margin of 18%based on $123 million in trailing 12-month revenue.</p>\n<p><b>Clover Health (CLOV)</b></p>\n<p>They say timing is everything.</p>\n<p>In early June, I wrote an article about the healthcare technology company, which uses data to provide healthcare plans for more than 130,000 Americans. At the time, I felt like there was a fair bit of&nbsp;upside resistance at $10.</p>\n<p>While I wouldn’t buy the money-losing stock, a patient investor with a higher than average risk tolerance would be wise to buy around $9, or hopefully less. And then came the June 8 Reddit-induced short squeeze, doubling CLOV’s share price within hours.</p>\n<p>“By afternoon trading [June 8], Clover had already traded over&nbsp;650 million shares, 30 times more than its 30-day average volume of 22 million shares, according to FactSet,”<i>CNBC</i>‘s Yun Lireported. “By the closing bell on Wall Street, more than 720 million shares had changed hands.”</p>\n<p>CLOV stock closed June 7 trading at $11.92. By 4 p.m. the next day, it was over $22.</p>\n<p>In my article, I mentioned the investing lesson a 17-year-old learned about managing your expectations when playing with real money. I really hope he was able to sell his call options in the June surge. If not, the shares have still doubled from a month ago.</p>\n<p>Overall, it’s down slightly from its&nbsp;first day of trading&nbsp;on Jan. 8.</p>\n<p>Clover has anFCF margin of -24.2%based on $721 million in trailing 12-month revenue.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Which of the 10 Most Talked About Reddit Stocks Is Worth a Buy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhich of the 10 Most Talked About Reddit Stocks Is Worth a Buy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-30 17:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/which-of-the-10-most-talked-about-reddit-stocks-is-worth-a-buy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Like all investments, there are good Reddit stocks, and bad ones\nSource: Marcus Krauss / Shutterstock.com\nI must admit, when I was given this assignment my first thought was I’m the last guy to be ...</p>\n\n<a href=\"https://investorplace.com/2021/06/which-of-the-10-most-talked-about-reddit-stocks-is-worth-a-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CLOV":"Clover Health Corp","KBH":"KB Home","CLNE":"Clean Energy Fuels Corp","TSLA":"特斯拉","BB":"黑莓","PLTR":"Palantir Technologies Inc.","WKHS":"Workhorse Group, Inc.","GSAT":"全球星","AMC":"AMC院线"},"source_url":"https://investorplace.com/2021/06/which-of-the-10-most-talked-about-reddit-stocks-is-worth-a-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150186389","content_text":"Like all investments, there are good Reddit stocks, and bad ones\nSource: Marcus Krauss / Shutterstock.com\nI must admit, when I was given this assignment my first thought was I’m the last guy to be talking about Reddit stocks. I think the attention being paid to Reddit and meme stocks is a bunch of hokum.\nThe arguments abound whether the meme stock frenzy is a permanent part of the investing landscape.\n“This is not going to end well,” Former E*Trade CEO Karl Roessner toldCNBCin early June while discussing the AMC rally. “I think historically we’ve seen this in the past, but I do believethis grouphas staying power.”\nHowever, if you’re a value investor, the mere presence of this kind of retail investor is music to your ears. While the sheep are out buying GameStop(NYSE:GME), you can pick up shares in some of America’s better companies that trade at a discount.\nThat’s not easy when the Cyclically Adjusted PE Ratio (CAPE) of 38.11 is at the second-highest level on record — the highest was in December 1999 — with no end in sight to the multiple’s upward trajectory.\nWith that in mind, I’ve rated the top 10 Reddit stocks— based on the number of comments made on r/WallStreetBets — from best to worst as a long-term buy:\n\nTesla(NASDAQ:TSLA)\nKB Home(NYSE:KBH)\nPalantir Technologies(NYSE:PLTR)\nClean Energy Fuels(NASDAQ:CLNE)\nBlackBerry(NYSE:BB)\nWorkhorse Group(NASDAQ:WKHS)\nAMC Entertainment(NYSE:AMC)\nContextLogic(NASDAQ:WISH)\nGlobalstar(NYSEAMERICAN:GSAT)\nClover Health(NASDAQ:CLOV)\n\nTesla (TSLA)\nSay what you will about Elon Musk, but there’s no question he’s built one heck of a company. Soon, Tesla will have a fourth factory open in Berlin. Even though the original opening date of July 1 is no longer on the table due to myriad reasons, it will ultimately produce millions of electric vehicles (EVs) for willing European buyers.\nThe company has added a battery cell production component to the plant outside Berlin. It will produce 500 million cells annually representing 50 gigawatt hours (GWh) of energy, 25% higher than Volkswagen’s(OTCMKTS:VWAGY) planned facility a couple hundred miles away.\nAcross the pond in Texas, the company’s fifth so-called Gigafactory is getting closer to being ready for production. This plant will produce an updated version of the Model Y using “mega casting” technology to speed up the production process while delivering a lighter vehicle at the same time. It currently uses this technology at its plant in Shanghai.\nTesla has afree cash flow (FCF) marginof 22.3% based on $35.94 billion in trailing-12-month revenue.\nKB Home (KBH)\nThe largest homebuilders in America are having trouble keeping up with demand at the moment. At least for now, KB Home is meeting the demand from customers, 64% of which were first-time buyers in the latest quarter.\n“Operationally, our divisions are doing an excellent job of navigating this environment of demand strength and well-publicized supply chain constraints as we effectively balanced pace, price and starts to optimize our assets and manage our production,” said KB Home CEO Jeff Mezger in the Q2 2021 conference call.\nKB Home is so busy that the number of homes started in Q1 2021 and Q2 2021 was equivalent to 75% of the number of homes started for 2020. As a result, it expects to deliver $6 billion in housing revenue in 2021 at the midpoint of guidance, with operating margins between 11.5% and 12.0%.\nKB Home has anFCF margin of 6.5%based on $4.78 billion in trailing 12-month revenue.\nPalantir Technologies (PLTR)\nPalantir has been a public company for less than a year. The provider of data analytics software platforms for government agencies, corporations, and other large institutions, sold no shares last September when directly listedon the NYSE.\nThe reference price was $7.25. PLTR stock is up 277.7% through the start of June 29.\nNot only is it growing its business — in the latest quarter, itsU.S. commercial revenuegrew 72% year-over-year while its U.S. government revenue jumped 83% YOY — it is also busy investing in other tech companies looking to go public.\nFor example, it has invested in six private investments in public equity (PIPE) in the past three months. These PIPEs are part of the ongoing interest in special purpose acquisition companies (SPACs). Palantir invests in the PIPEs to gain financial returns and collaborate with these companies, which use its data analytic tools for their businesses.\nI’m not 100% sold on Palantir just yet, but it’s a good long-term buy compared to some of the Reddit stocks on this list.\nPalantir has anFCF margin of 9%based on $1.2 billion in trailing 12-month revenue.\nClean Energy Fuels(CLNE)\nBack in February,I recommended CLNE. At the time, it was trading around $12.97. It was one of seven stocks to buy under $20. As I write this, it’s just under $11, so it’s lost ground over the past four months.\nI liked Clean Energy for several reasons.\nFirst, it provides three kinds of natural gas fuel for commercial trucks: compressed (CNG), liquified (LNG), and renewable (RNG). It’s the only fuel provider to do so. Secondly, RNG fuel enables trucking companies to deliver their services while getting close to or achieving carbon negative status. Third, it’s got fueling stations in 43 states and Canada. Lastly, it’s got deep pockets.Total(OTCMKTS:TTFNF) owns 25% of its stock.\nOh, and as I said in February, from an adjusted EBITDA basis (earnings before interest, taxes, depreciation and amortization), it makes money while also growing revenues at a steady pace.\nIn the meantime, Clean Energy has anFCF margin of 24.2%based on $283 million in trailing 12-month revenue.\nBlackBerry (BB)\nI can remember when President Barack Obama first entered the White House in January 2009. The BlackBerry was considered the cat’s meow when it came to mobile phones. By the time he left office in January 2017, it was in the dustbin of history.\nNow supplying security software to automobile manufacturers and other enterprises and governments worldwide — a research firm recently said its QNX software is installed in195 million vehicles worldwide — the Reddit crowd have taken to the Waterloo, Ontario-based tech company.\nThings have turned around for BlackBerry.\nAt least, enough so to provide CEO John Chen with a handsome compensation package. Proxy advisory firm Glass Lewis recently blasted the company, suggesting its compensation plan had no relation to its overall corporate performance.\nAs a result of the January Reddit rally, which saw BB stock move from $6.70 at the beginning of the month to a 52-week high of $28.77 by the end, Chen could receive as much as $206 million in cash and stock compensation from the long-term incentives issued in 2019.\nOn a GAAP basis,BlackBerry still loses money. That said, the pivot it’s made to software has given it another shot at tech stardom. We’ll see if it gain regain its former glory from the Obama years.\nIn the meantime, BlackBerry has anFCF margin of 9.3%based on $861 million in trailing 12-month revenue.\nWorkhorse Group (WKHS)\nThe last time I wrote about Workhorse Group was in late April. At the time, it was trading around $12.50. I argued that if it got the backlog of 8,000 commercial electric vehicle delivery trucks out the door over the next 12 to 24 months, it would have an ultra-low price-to-sales ratio of 4.2.\nLong story short, if it did, its stock would be worth more than $12.50.\nWell, on June 16, Workhorse officially protested the United States Postal Service awarding the estimated $6 billion contract to manufacture its next-generation delivery vehicle to Oshkosh(NYSE:OSK). The news pushed WKHS to $17.54 at the start of June 29.\nInvestorPlace’s Dana Blankenhorn recently discussed Workhorse. He believes that the company was in the commercial EV game to ride on the coattails of big guns like Ford(NYSE:F) and General Motors(NYSE:GM). That’s not the craziest theory in the world.\nIn the latest quarter, Workhorse delivered six trucks to customers and generated $521,000 in revenue. It plans to produce 1,000 trucks in 2021. It will have to pick up the pace if it wants to reach that goal. In the meantime, investors can expect its quarterly losses to accelerate as we make our way through the year.\nWorkhorse has an FCF margin of -5,320.2% based on $1.83 million in trailing 12-month revenue. It is for speculative investors only.\nAMC Entertainment (AMC)\nAMC is a stock that I’m conflicted about.\nOn the one hand, I believe that Americans will return to movie theaters in large numbers come fall. That will likely return the chain to pre-Covid revenue numbers. On the other hand, it has a burdensome debt load.\nDespite using the Reddit surge to raise much-needed cash to repay some of this debt — on June 3, it announced it would sell 11.55 million shares at the market to bring in another $600 million— it still has $11.05 billion owed, or 37.6% of its vastly overvalued market capitalization of $29.4 billion.\nFormer E*Trade CEO Karl Roessner appeared on CNBC in early June. While he commended AMC management for selling shares when prices were high, the company is not worth $28 billion.\n“Absent some serious strategic undertakings by that company, it’s still just not worth what it’s trading for right now,” Roessner stated.\nI couldn’t agree more.\nAMC has anFCF margin of -280%based on $449 million in trailing 12-month revenue.\nContextLogic (WISH)\nIn February, I wrote an article about the e-commerce site with the headline“ContextLogic Has Nothing to Do With Retail”.I didn’t understand the composition of its board. It had no retail experience on its board to oversee the CEO.\n“If ContextLogic’s goal is to beat Amazon(NASDAQ:AMZN) at discount e-commerce apparel, its board of directors is a sure sign that’s not what it’s after,” I said.\nI finished the article by stating I didn’t get an inspirational vibe from Context Logic’s board of directors. In the four months since, WISH has lost 49% of its value and trades well below its IPO price of $24.\nContextLogic has anFCF margin of -8%based on $2.87 billion in trailing 12-month revenue. I’m really not sure what Redditors see in this one.\nGlobalstar (GSAT)\nNot everyone thinks the provider of mobile satellite services is a bad bet.\nB. Riley analyst Mike Crawford initiated coverage of Globalstar on June 21. The analyst gives it a “buy” rating and a $3.25 target price, double where it’s currently trading. He estimates that the company’s C-Band spectrum could be worth as much as $15 billion. Based on 1.79 billion shares outstanding, that’s $8.38 a share, considerably higher than the analyst’s target price.\nFrom where I sit, the fact that it’s currently trading at a price-to-sales ratio of 25.39 and not making money on a GAAP basis makes it very hard for me to get behind the company.\nHowever, Globalstar does have one big ace up its sleeve.\nOn page 87 of its 2020 10-K, you will see that it had $1.8 billion in U.S. net operating loss (NOL) carryforwards with less than 1% expiring before 2025. It has an additional $200 million in foreign NOL carryforwards. So, should it start generating significant profits — that’s still very much up in the air — the loss carryforwards will shield the company’s earnings from taxes for the foreseeable future.\nGlobalstar has anFCF margin of 18%based on $123 million in trailing 12-month revenue.\nClover Health (CLOV)\nThey say timing is everything.\nIn early June, I wrote an article about the healthcare technology company, which uses data to provide healthcare plans for more than 130,000 Americans. At the time, I felt like there was a fair bit of upside resistance at $10.\nWhile I wouldn’t buy the money-losing stock, a patient investor with a higher than average risk tolerance would be wise to buy around $9, or hopefully less. And then came the June 8 Reddit-induced short squeeze, doubling CLOV’s share price within hours.\n“By afternoon trading [June 8], Clover had already traded over 650 million shares, 30 times more than its 30-day average volume of 22 million shares, according to FactSet,”CNBC‘s Yun Lireported. “By the closing bell on Wall Street, more than 720 million shares had changed hands.”\nCLOV stock closed June 7 trading at $11.92. By 4 p.m. the next day, it was over $22.\nIn my article, I mentioned the investing lesson a 17-year-old learned about managing your expectations when playing with real money. I really hope he was able to sell his call options in the June surge. If not, the shares have still doubled from a month ago.\nOverall, it’s down slightly from its first day of trading on Jan. 8.\nClover has anFCF margin of -24.2%based on $721 million in trailing 12-month revenue.","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":177502759,"gmtCreate":1627234211971,"gmtModify":1633767007886,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"likee","listText":"likee","text":"likee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/177502759","repostId":"2153878189","repostType":4,"isVote":1,"tweetType":1,"viewCount":239,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":175923926,"gmtCreate":1627003255665,"gmtModify":1633768893080,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"eow","listText":"eow","text":"eow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/175923926","repostId":"1164478982","repostType":4,"repost":{"id":"1164478982","kind":"news","pubTimestamp":1626995319,"share":"https://www.laohu8.com/m/news/1164478982?lang=&edition=full","pubTime":"2021-07-23 07:08","market":"us","language":"en","title":"Wall Street ekes out gains, led by tech, growth stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=1164478982","media":"Reuters","summary":"NEW YORK  - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks.A pull-back in economically sensitive cyclicals kept the S&P 500’s and the blue-chip Dow’s gains muted, while small-caps underperformed their larger rivals.“The market is flip-flopping between the view that economic growth has almost peaked so you need to buy stocks that manufacture thei","content":"<p>NEW YORK (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks.</p>\n<p>A pull-back in economically sensitive cyclicals kept the S&amp;P 500’s and the blue-chip Dow’s gains muted, while small-caps underperformed their larger rivals.</p>\n<p>But megacap tech and tech-adjacent stocks, such as Microsoft Corp, Amazon.com, Apple Inc, <a href=\"https://laohu8.com/S/FB\">Facebook</a> Inc and Alphabet Inc, rose ahead of their quarterly results next week, putting the Nasdaq out front.</p>\n<p>All three major U.S. stock indexes ended the session within 1% of their record closing highs.</p>\n<p>Growth stocks, which outperformed throughout the health crisis, were back in favor, gaining 0.8%, while the value index slipped by 0.5%.</p>\n<p>“The market is flip-flopping between the view that economic growth has almost peaked so you need to buy stocks that manufacture their own growth like tech names, versus the view that economic growth will continue and you want to own cyclicals and value names,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York.</p>\n<p>The number of U.S. workers filing first-time applications for unemployment benefits spiked unexpectedly to 419,000 last week, a two-month high, according to the Labor Department.</p>\n<p>Market participants are closely watching labor market indicators for hints as to when the Federal Reserve, expected to convene next week for its two-day monetary policy meeting, will begin discussions about hiking key interest rates from near zero.</p>\n<p>“The jobless data today didn’t have a meaningful impact on markets or the economic outlook,” Carter added. “It’s now all about how much longer the Fed will tolerate low rates. The Fed seems to be favoring its full employment mandate more than its price stability mandate.”</p>\n<p>“Accordingly, the upcoming Fed meeting could be impactful,” Carter said.</p>\n<p>Benchmark Treasury yields eased after the bid at the largest-ever TIPS auction touched a record low, pressuring rate sensitive banks.</p>\n<p>The Dow Jones Industrial Average rose 25.35 points, or 0.07%, to 34,823.35, the S&amp;P 500 gained 8.79 points, or 0.20%, to 4,367.48 and the Nasdaq Composite added 52.64 points, or 0.36%, to 14,684.60.</p>\n<p>Of the 11 major sectors of the S&amp;P 500, tech was shining brightest, gaining 0.7%. Energy stocks suffered the largest percentage drop.</p>\n<p>The second-quarter reporting season barreled ahead at full-throttle, with 104 of the companies in the S&amp;P 500 having reported. Of those, 88% have beaten consensus estimates, according to Refinitiv.</p>\n<p>Drugmaker Biogen Inc gained 1.1% after hiking its full-year revenue guidance, while Domino’s Pizza Inc surged 14.6% to an all-time high on the heels of its quarterly report.</p>\n<p>Southwest Airlines Co posted a bigger-than-expected quarterly loss, sending its stock down 3.5%, and American Airlines Group Inc dipped 1.1% even after reporting a quarterly profit.</p>\n<p>The S&amp;P 1500 Airlines index ended the session off 1.7%.</p>\n<p>Shares of Texas Instruments Inc slid 5.3% after its current-quarter revenue forecast cast concerns as to whether the company will be able to meet spiking demand in the face of a global semiconductor shortage.</p>\n<p>The Philadelphia SE Semiconductor index ended the session down 0.9%.</p>\n<p>Chipmaker Intel Corp slipped more than 1% in extended trading after the chipmaker posted results and raised its annual revenue forecast.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.82-to-1 ratio; on Nasdaq, a 1.90-to-1 ratio favored decliners.</p>\n<p>The S&amp;P 500 posted 39 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 54 new lows.</p>\n<p>Volume on U.S. exchanges was 8.25 billion shares, compared with the 10.12 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ekes out gains, led by tech, growth stocks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ekes out gains, led by tech, growth stocks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-23 07:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/article/usa-stocks/us-stocks-wall-street-ekes-out-gains-led-by-tech-growth-stocks-idUSL1N2OY2HH><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NEW YORK (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot ...</p>\n\n<a href=\"https://www.reuters.com/article/usa-stocks/us-stocks-wall-street-ekes-out-gains-led-by-tech-growth-stocks-idUSL1N2OY2HH\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.reuters.com/article/usa-stocks/us-stocks-wall-street-ekes-out-gains-led-by-tech-growth-stocks-idUSL1N2OY2HH","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164478982","content_text":"NEW YORK (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks.\nA pull-back in economically sensitive cyclicals kept the S&P 500’s and the blue-chip Dow’s gains muted, while small-caps underperformed their larger rivals.\nBut megacap tech and tech-adjacent stocks, such as Microsoft Corp, Amazon.com, Apple Inc, Facebook Inc and Alphabet Inc, rose ahead of their quarterly results next week, putting the Nasdaq out front.\nAll three major U.S. stock indexes ended the session within 1% of their record closing highs.\nGrowth stocks, which outperformed throughout the health crisis, were back in favor, gaining 0.8%, while the value index slipped by 0.5%.\n“The market is flip-flopping between the view that economic growth has almost peaked so you need to buy stocks that manufacture their own growth like tech names, versus the view that economic growth will continue and you want to own cyclicals and value names,” said David Carter, chief investment officer at Lenox Wealth Advisors in New York.\nThe number of U.S. workers filing first-time applications for unemployment benefits spiked unexpectedly to 419,000 last week, a two-month high, according to the Labor Department.\nMarket participants are closely watching labor market indicators for hints as to when the Federal Reserve, expected to convene next week for its two-day monetary policy meeting, will begin discussions about hiking key interest rates from near zero.\n“The jobless data today didn’t have a meaningful impact on markets or the economic outlook,” Carter added. “It’s now all about how much longer the Fed will tolerate low rates. The Fed seems to be favoring its full employment mandate more than its price stability mandate.”\n“Accordingly, the upcoming Fed meeting could be impactful,” Carter said.\nBenchmark Treasury yields eased after the bid at the largest-ever TIPS auction touched a record low, pressuring rate sensitive banks.\nThe Dow Jones Industrial Average rose 25.35 points, or 0.07%, to 34,823.35, the S&P 500 gained 8.79 points, or 0.20%, to 4,367.48 and the Nasdaq Composite added 52.64 points, or 0.36%, to 14,684.60.\nOf the 11 major sectors of the S&P 500, tech was shining brightest, gaining 0.7%. Energy stocks suffered the largest percentage drop.\nThe second-quarter reporting season barreled ahead at full-throttle, with 104 of the companies in the S&P 500 having reported. Of those, 88% have beaten consensus estimates, according to Refinitiv.\nDrugmaker Biogen Inc gained 1.1% after hiking its full-year revenue guidance, while Domino’s Pizza Inc surged 14.6% to an all-time high on the heels of its quarterly report.\nSouthwest Airlines Co posted a bigger-than-expected quarterly loss, sending its stock down 3.5%, and American Airlines Group Inc dipped 1.1% even after reporting a quarterly profit.\nThe S&P 1500 Airlines index ended the session off 1.7%.\nShares of Texas Instruments Inc slid 5.3% after its current-quarter revenue forecast cast concerns as to whether the company will be able to meet spiking demand in the face of a global semiconductor shortage.\nThe Philadelphia SE Semiconductor index ended the session down 0.9%.\nChipmaker Intel Corp slipped more than 1% in extended trading after the chipmaker posted results and raised its annual revenue forecast.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.82-to-1 ratio; on Nasdaq, a 1.90-to-1 ratio favored decliners.\nThe S&P 500 posted 39 new 52-week highs and no new lows; the Nasdaq Composite recorded 70 new highs and 54 new lows.\nVolume on U.S. exchanges was 8.25 billion shares, compared with the 10.12 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":146166813,"gmtCreate":1626059876532,"gmtModify":1633930529995,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"omy oof","listText":"omy oof","text":"omy oof","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/146166813","repostId":"2150076873","repostType":4,"repost":{"id":"2150076873","kind":"highlight","pubTimestamp":1626058200,"share":"https://www.laohu8.com/m/news/2150076873?lang=&edition=full","pubTime":"2021-07-12 10:50","market":"us","language":"en","title":"A Stock Market Crash Is Coming: 3 Top Stocks to Buy When It Happens","url":"https://stock-news.laohu8.com/highlight/detail?id=2150076873","media":"Motley Fool","summary":"The next crash is a matter of when, not if. When it hits, you may want to pounce on these stocks.","content":"<p>Stock market crashes tend to be painful, but they also create chances to invest in great companies at huge discounts. Nabbing the right stocks when these opportunities arise can be a path to life-changing returns.</p>\n<p>With that in mind, a panel of Motley Fool contributors has identified three stocks that are worth going big on when the next crash hits. Read on to see why these companies top their \"buy lists\" for the next time the stock market goes on sale.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F633163%2Fcharts-and-numbers-over-a-hundred-dollar-bill.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"453\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>CrowdStrike Holdings</h3>\n<p><b>Keith Noonan:&nbsp;CrowdStrike&nbsp;</b>(NASDAQ:CRWD) provides cloud-based cybersecurity services that help prevent devices including laptops, mobile hardware, and servers from being exploited by hackers and other bad actors. The company, a leader in its corner of the industry, has a strong outlook for growth even if overall economic conditions should weaken.</p>\n<p>The cybersecurity specialist has already been growing at a rapid clip, managing to increase its revenue 70% year over year last quarter and 82% in the last fiscal year. Impressive sales momentum has helped push CrowdStrike's share price up over 130% over the last 12 months, and the company looks poised to benefit from strong-demand tailwinds through the next decade and beyond.</p>\n<p>As business and communications are increasingly carried out through digital channels, the risks and damages caused by cyberattacks are soaring. Cybersecurity services will only become increasingly important as bad actors have rising incentives to exploit vulnerabilities and gain access to network systems, and CrowdStrike's AI-powered software is providing best-in-class solutions. The company's Falcon platform learns from each new threat that it encounters, creating a service that offers improving value for customers.</p>\n<p>Valued at roughly $59 billion and trading at approximately 43 times this year's expected sales, CrowdStrike has a highly growth-dependent valuation. That suggests the stock could be primed for a substantial pullback when the next market crash rolls around. But demand for the company's service expertise should remain pretty healthy and help the stock bounce back and reach new heights.</p>\n<h3><b><a href=\"https://laohu8.com/S/FB\">Facebook</a></b></h3>\n<p><b>Jamal Carnette: </b>Big Tech's relationship with Washington lawmakers can best be classified as \"it's complicated.\" Just a few years ago politicians were trumpeting the \"new economy\"; now companies like <b>Facebook</b> (NASDAQ:FB) are firmly in DC's crosshairs. Last month, the House of Representatives voted on six bills designed to regulate the tech industry.</p>\n<p>Understandably, Facebook investors are worried about increased regulatory and legal risk, but proper perspective is warranted. Generally, less than 5% of all bills become laws, and most tend to be less impactful than the initial versions. Additionally, Facebook will have the ability to fight legislation through the court system. Recently, it did just that and scored a win against the Federal Trade Commission.</p>\n<p>Facebook is primed for growth. Last year grew revenue 22% as the pandemic slammed digital advertisers from the travel and leisure industries. The overall digital-marketing industry grew 7%. This year, the industry expects growth rates three times last year's figure, which will disproportionally benefit Facebook and <b>Alphabet</b>, and both will continue to win share by growing at higher rates than the overall market.</p>\n<p>Despite its recent performance, Facebook stock still trades at a reasonable valuation. Currently, shares trade at 29.6 times earnings versus 27.3 times from the greater <b>S&amp;P 500</b>. The price/earnings-to-growth (PEG) ratio -- which factors in the expected earnings growth to the figures above -- is 1.2, a figure in value stock territory. When a crash comes, investors should use the opportunity to pick up Facebook shares on the cheap.</p>\n<h3>The Trade Desk</h3>\n<p><b>Jason Hall:</b> It's been an incredible run for <b>The Trade Desk</b> (NASDAQ:TTD) investors, with the ad-tech stock generating almost 2,500% in total returns since going public less than five years ago.</p>\n<p>Yet even with this incredible run, I expect that The Trade Desk will continue to deliver market-beating returns for years to come as more and more advertising dollars shift away from linear TV and other platforms and move to programmatic ad platforms.&nbsp;And that's a huge tailwind for the company, which is partnered with some of the world's largest ad agencies, positioning it for plenty more growth to come.</p>\n<p>On the other side of the coin, The Trade Desk has been and is likely to remain a&nbsp;<i>very&nbsp;</i>volatile stock. We saw this play out to the extreme during the 2020 coronavirus crash when shares plummeted more than 50% in less than two months:</p>\n<p><img src=\"https://static.tigerbbs.com/3765fe7042929f5eecdc9cc10d7ac51f\" tg-width=\"720\" tg-height=\"433\" referrerpolicy=\"no-referrer\"></p>\n<p>TTD data by YCharts</p>\n<p>As the chart above shows, it's not uncommon for The Trade Desk stock to fall more than 30% from its recent high; shares are actually still down about 20% from the recent high as of this writing.</p>\n<p>Add it all up, and The Trade Desk is a great growth stock because of its prospects. But it's also <a href=\"https://laohu8.com/S/AONE\">one</a> that's worth adding to your portfolio over time when Mr. Market gives you opportunities to buy. There's a very good chance that the next market crash will prove to be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of those&nbsp; opportunities.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Stock Market Crash Is Coming: 3 Top Stocks to Buy When It Happens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Stock Market Crash Is Coming: 3 Top Stocks to Buy When It Happens\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-12 10:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/11/a-stock-market-crash-is-coming-3-top-stocks-to-buy/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stock market crashes tend to be painful, but they also create chances to invest in great companies at huge discounts. Nabbing the right stocks when these opportunities arise can be a path to life-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/11/a-stock-market-crash-is-coming-3-top-stocks-to-buy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CRWD":"CrowdStrike Holdings, Inc.","TTD":"Trade Desk Inc."},"source_url":"https://www.fool.com/investing/2021/07/11/a-stock-market-crash-is-coming-3-top-stocks-to-buy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2150076873","content_text":"Stock market crashes tend to be painful, but they also create chances to invest in great companies at huge discounts. Nabbing the right stocks when these opportunities arise can be a path to life-changing returns.\nWith that in mind, a panel of Motley Fool contributors has identified three stocks that are worth going big on when the next crash hits. Read on to see why these companies top their \"buy lists\" for the next time the stock market goes on sale.\n\nImage source: Getty Images.\nCrowdStrike Holdings\nKeith Noonan: CrowdStrike (NASDAQ:CRWD) provides cloud-based cybersecurity services that help prevent devices including laptops, mobile hardware, and servers from being exploited by hackers and other bad actors. The company, a leader in its corner of the industry, has a strong outlook for growth even if overall economic conditions should weaken.\nThe cybersecurity specialist has already been growing at a rapid clip, managing to increase its revenue 70% year over year last quarter and 82% in the last fiscal year. Impressive sales momentum has helped push CrowdStrike's share price up over 130% over the last 12 months, and the company looks poised to benefit from strong-demand tailwinds through the next decade and beyond.\nAs business and communications are increasingly carried out through digital channels, the risks and damages caused by cyberattacks are soaring. Cybersecurity services will only become increasingly important as bad actors have rising incentives to exploit vulnerabilities and gain access to network systems, and CrowdStrike's AI-powered software is providing best-in-class solutions. The company's Falcon platform learns from each new threat that it encounters, creating a service that offers improving value for customers.\nValued at roughly $59 billion and trading at approximately 43 times this year's expected sales, CrowdStrike has a highly growth-dependent valuation. That suggests the stock could be primed for a substantial pullback when the next market crash rolls around. But demand for the company's service expertise should remain pretty healthy and help the stock bounce back and reach new heights.\nFacebook\nJamal Carnette: Big Tech's relationship with Washington lawmakers can best be classified as \"it's complicated.\" Just a few years ago politicians were trumpeting the \"new economy\"; now companies like Facebook (NASDAQ:FB) are firmly in DC's crosshairs. Last month, the House of Representatives voted on six bills designed to regulate the tech industry.\nUnderstandably, Facebook investors are worried about increased regulatory and legal risk, but proper perspective is warranted. Generally, less than 5% of all bills become laws, and most tend to be less impactful than the initial versions. Additionally, Facebook will have the ability to fight legislation through the court system. Recently, it did just that and scored a win against the Federal Trade Commission.\nFacebook is primed for growth. Last year grew revenue 22% as the pandemic slammed digital advertisers from the travel and leisure industries. The overall digital-marketing industry grew 7%. This year, the industry expects growth rates three times last year's figure, which will disproportionally benefit Facebook and Alphabet, and both will continue to win share by growing at higher rates than the overall market.\nDespite its recent performance, Facebook stock still trades at a reasonable valuation. Currently, shares trade at 29.6 times earnings versus 27.3 times from the greater S&P 500. The price/earnings-to-growth (PEG) ratio -- which factors in the expected earnings growth to the figures above -- is 1.2, a figure in value stock territory. When a crash comes, investors should use the opportunity to pick up Facebook shares on the cheap.\nThe Trade Desk\nJason Hall: It's been an incredible run for The Trade Desk (NASDAQ:TTD) investors, with the ad-tech stock generating almost 2,500% in total returns since going public less than five years ago.\nYet even with this incredible run, I expect that The Trade Desk will continue to deliver market-beating returns for years to come as more and more advertising dollars shift away from linear TV and other platforms and move to programmatic ad platforms. And that's a huge tailwind for the company, which is partnered with some of the world's largest ad agencies, positioning it for plenty more growth to come.\nOn the other side of the coin, The Trade Desk has been and is likely to remain a very volatile stock. We saw this play out to the extreme during the 2020 coronavirus crash when shares plummeted more than 50% in less than two months:\n\nTTD data by YCharts\nAs the chart above shows, it's not uncommon for The Trade Desk stock to fall more than 30% from its recent high; shares are actually still down about 20% from the recent high as of this writing.\nAdd it all up, and The Trade Desk is a great growth stock because of its prospects. But it's also one that's worth adding to your portfolio over time when Mr. Market gives you opportunities to buy. There's a very good chance that the next market crash will prove to be one of those  opportunities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":51,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":141322355,"gmtCreate":1625839619777,"gmtModify":1633936818205,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"ohman","listText":"ohman","text":"ohman","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/141322355","repostId":"1187480487","repostType":4,"repost":{"id":"1187480487","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1625838849,"share":"https://www.laohu8.com/m/news/1187480487?lang=&edition=full","pubTime":"2021-07-09 21:54","market":"us","language":"en","title":"Disney shares rises nearly 2%,as Shanghai Disneyland raising prices up to 10%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1187480487","media":"Tiger Newspress","summary":"Disney shares rises nearly 2%,as Shanghai Disneyland raising prices up to 10%.\n\n\nShanghai Disneyland","content":"<p>Disney&nbsp;shares&nbsp;rises&nbsp;nearly&nbsp;2%,as&nbsp;Shanghai Disneyland raising prices up to 10%.</p>\n<p><img src=\"https://static.tigerbbs.com/c8b245ccacada732569aab91c7bad577\" tg-width=\"803\" tg-height=\"601\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>Shanghai Disneyland (DIS+0.7%) willraise its ticket prices starting in January.</li>\n <li>The resort indicated it would boost prices on Jan. 9, setting new rates for four tiers: Regular, Regular Plus, Peak (most days in summer season and other peak visitation days), and Peak Plus.</li>\n <li>The Regular price at that time will be 435 yuan (about $67.13). Regular Plus will be 545 yuan (about $84.11). Meanwhile, Peak price is set at 659 yuan ($101.70) and Peak Plus at 769 yuan ($118.67).</li>\n <li>That results in increases of 9-10% across the board.</li>\n <p><b>Disney</b>&nbsp;is gearing up for a big weekend at the box office as the long-delayed \"Black Widow\" is set for its theatrical release worldwide on July 9. Disney stock rose.</p>\n <p>Worldwide estimates for \"Black Widow\" are as high as $140 million, according to Deadline. That doesn't include China, Marvel's biggest market, as it doesn't yet have a release date there.</p>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney shares rises nearly 2%,as Shanghai Disneyland raising prices up to 10%.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney shares rises nearly 2%,as Shanghai Disneyland raising prices up to 10%.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-07-09 21:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Disney&nbsp;shares&nbsp;rises&nbsp;nearly&nbsp;2%,as&nbsp;Shanghai Disneyland raising prices up to 10%.</p>\n<p><img src=\"https://static.tigerbbs.com/c8b245ccacada732569aab91c7bad577\" tg-width=\"803\" tg-height=\"601\" referrerpolicy=\"no-referrer\"></p>\n<ul>\n <li>Shanghai Disneyland (DIS+0.7%) willraise its ticket prices starting in January.</li>\n <li>The resort indicated it would boost prices on Jan. 9, setting new rates for four tiers: Regular, Regular Plus, Peak (most days in summer season and other peak visitation days), and Peak Plus.</li>\n <li>The Regular price at that time will be 435 yuan (about $67.13). Regular Plus will be 545 yuan (about $84.11). Meanwhile, Peak price is set at 659 yuan ($101.70) and Peak Plus at 769 yuan ($118.67).</li>\n <li>That results in increases of 9-10% across the board.</li>\n <p><b>Disney</b>&nbsp;is gearing up for a big weekend at the box office as the long-delayed \"Black Widow\" is set for its theatrical release worldwide on July 9. Disney stock rose.</p>\n <p>Worldwide estimates for \"Black Widow\" are as high as $140 million, according to Deadline. That doesn't include China, Marvel's biggest market, as it doesn't yet have a release date there.</p>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187480487","content_text":"Disney shares rises nearly 2%,as Shanghai Disneyland raising prices up to 10%.\n\n\nShanghai Disneyland (DIS+0.7%) willraise its ticket prices starting in January.\nThe resort indicated it would boost prices on Jan. 9, setting new rates for four tiers: Regular, Regular Plus, Peak (most days in summer season and other peak visitation days), and Peak Plus.\nThe Regular price at that time will be 435 yuan (about $67.13). Regular Plus will be 545 yuan (about $84.11). Meanwhile, Peak price is set at 659 yuan ($101.70) and Peak Plus at 769 yuan ($118.67).\nThat results in increases of 9-10% across the board.\nDisney is gearing up for a big weekend at the box office as the long-delayed \"Black Widow\" is set for its theatrical release worldwide on July 9. Disney stock rose.\nWorldwide estimates for \"Black Widow\" are as high as $140 million, according to Deadline. That doesn't include China, Marvel's biggest market, as it doesn't yet have a release date there.","news_type":1},"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887349558,"gmtCreate":1631982686474,"gmtModify":1632804968350,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"oof","listText":"oof","text":"oof","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/887349558","repostId":"2168957763","repostType":4,"repost":{"id":"2168957763","kind":"news","pubTimestamp":1631950800,"share":"https://www.laohu8.com/m/news/2168957763?lang=&edition=full","pubTime":"2021-09-18 15:40","market":"us","language":"en","title":"FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations","url":"https://stock-news.laohu8.com/highlight/detail?id=2168957763","media":"StreetInsider","summary":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization ti","content":"<ul>\n <li><i>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants </i></li>\n <li><i>Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series</i></li>\n <li><i>Real-world data presented by Israel Ministry of Health show additional protection after receiving a</i> <i>booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine</i> <i>rollout</i></li>\n <li><i>FDA expected to make its decision in the coming days </i></li>\n</ul>\n<p><b>NEW YORK AND MAINZ, GERMANY, September 17, 2021</b>—Pfizer Inc. (NYSE: PFE) and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.</p>\n<p>VRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.</p>\n<p>At this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.</p>\n<p>The FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.</p>\n<p>“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said <b>Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research &amp; Development, Pfizer</b>. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”</p>\n<p>“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said <b>Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.</b></p>\n<p>VRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.</p>\n<p>Real-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in <i>The New England Journal of Medicine</i>. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.</p>\n<p>Under the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was <u>previously authorized</u> for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.</p>\n<p>COMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.</p>\n<p><b>U.S. Indication &amp; Authorized Use</b>COMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.</p>\n<ul>\n <li>It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older</li>\n <li>It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:</li>\n</ul>\n<p>The Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:</p>\n<ul>\n <li>prevent COVID-19 in individuals 12 years of age and older, and</li>\n <li>provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise</li>\n</ul>\n<p>The FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.</p>\n<p><b>EUA Statement</b>This emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&amp;C Act unless the declaration is terminated or authorization revoked sooner.</p>\n<p><b>Important Safety Information</b>Individuals should <b>not</b> get the Pfizer-BioNTech COVID-19 Vaccine if they:</p>\n<ul>\n <li>had a severe allergic reaction after a previous dose of this vaccine</li>\n <li>had a severe allergic reaction to any ingredient of this vaccine</li>\n</ul>\n<p>Individuals should tell the vaccination provider about all of their medical conditions, including if they:</p>\n<ul>\n <li>have any allergies</li>\n <li>have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)</li>\n <li>have a fever</li>\n <li>have a bleeding disorder or are on a blood thinner</li>\n <li>are immunocompromised or are on a medicine that affects the immune system</li>\n <li>are pregnant, plan to become pregnant, or are breastfeeding</li>\n <li>have received another COVID-19 vaccine</li>\n <li>have ever fainted in association with an injection</li>\n</ul>\n<p>The vaccine may not protect everyone.</p>\n<p>Side effects reported with the vaccine include:</p>\n<ul>\n <li>There is a remote chance that the vaccine could cause a severe allergic reaction</li>\n <li>Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:</li>\n <li>Side effects that have been reported with the vaccine include:</li>\n <li>These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away</li>\n</ul>\n<p>There is no information on the use of the vaccine with other vaccines.</p>\n<p>Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit <u>http://www.vaers.hhs.gov</u> or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at <u>www.pfizersafetyreporting.com</u> or by calling 1-800-438-1985.</p>\n<p>Please <u>click here</u> for full Prescribing Information (16+ years of age). Please <u>click here</u> for Fact Sheet for Vaccination Providers (12+ years of age).</p>\n<p><b>About Pfizer: Breakthroughs That Change Patients’ Lives</b>At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at <u>www.Pfizer.com</u>. In addition, to learn more, please visit us on <u>www.Pfizer.com</u> and follow us on <a href=\"https://laohu8.com/S/TWTR\">Twitter</a> at <u>@Pfizer</u> and <u>@Pfizer News</u>, <u>LinkedIn</u>, <u>YouTube</u> and like us on <a href=\"https://laohu8.com/S/FB\">Facebook</a> at <u>Facebook.com/Pfizer</u>.</p>\n<p><b>Pfizer Disclosure Notice</b>The information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>\n<p>This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p>\n<p>A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at <u>www.sec.gov</u> and <u>www.pfizer.com</u>.</p>\n<p><b>About BioNTech</b>Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a>, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit <u>www.BioNTech.de</u>.</p>\n<p><b>BioNTech Forward-looking Statements</b>This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.</p>\n<p>For a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at <u>www.sec.gov</u>. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-18 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=18955632><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18955632\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18955632","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168957763","content_text":"Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants \nReactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series\nReal-world data presented by Israel Ministry of Health show additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout\nFDA expected to make its decision in the coming days \n\nNEW YORK AND MAINZ, GERMANY, September 17, 2021—Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose of COMIRNATY® (COVID-19 Vaccine, mRNA) in individuals 65 years of age and older and individuals at high risk of severe COVID-19. The committee recommended that the additional dose be administered at least six months after the two-dose series. The panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this EUA.\nVRBPAC is made up of independent experts who advise the FDA on scientific and regulatory matters, including the evaluation of vaccine safety and efficacy.\nAt this time, VRBPAC did not vote in favor of approval of a booster dose for the full population for which Pfizer and BioNTech submitted their supplemental Biologics License Application, which was individuals 16 and older. The same data have recently been submitted to the European Medicines Agency (EMA) and will be filed with other regulatory authorities in the coming weeks. The companies remain vigilant and continue to generate relevant COMIRNATY booster dose data for evaluation for future licensure in further groups as well as to address emerging variants of concern.\nThe FDA is expected to make its decision in the coming days. This decision could allow COMIRNATY to be the first COVID-19 vaccine with a booster authorized in the U.S.\n“Today the VRBPAC reviewed data from our clinical program showing a favorable safety profile and strong immune responses against SARS-CoV-2 after a booster dose of our vaccine. These data, and the larger body of scientific evidence presented at the meeting, underscore our belief that boosters can be a critical tool in the ongoing effort to control the spread of this virus,” said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We thank the committee for their thoughtful review of the data and will work with the FDA following today’s meeting to address the committee’s questions, as we continue to believe in the benefits of a booster dose for a broader population.”\n“We are committed to support the ongoing efforts to reduce infections and COVID-19 cases. The data we submitted to the FDA, EMA and other regulatory authorities underline that a booster induces a strong immune response against all tested variants of concern and may contribute to address a public health need,” said Özlem Türeci, M.D., Co-founder and Chief Medical Officer of BioNTech.\nVRBPAC based its recommendation on the totality of scientific evidence shared by the companies, including data from their clinical program evaluating the safety, tolerability and immunogenicity of a booster dose of COMIRNATY. A booster dose of the vaccine elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), as well as the Beta and Delta variants, when compared with the levels observed after the two-dose primary series. The reactogenicity profile within seven days after the booster dose was typically mild to moderate, and the frequency of reactions was similar to or lower than after dose two. The adverse event profile was generally consistent with other clinical safety data for COMIRNATY.\nReal-world surveillance data also were presented to the VRBPAC by the Israel Ministry of Health, providing further support for the public health impact of boosters. The data presented from Israel included an analysis published this week in The New England Journal of Medicine. The analysis comprised approximately 1.1 million individuals ages 60 years and older who were eligible for a booster dose of the vaccine between July 30 through August 31, 2021. No new safety signals were observed, and reported adverse events were lower than those observed after dose two. The analysis showed that a booster dose restored very high levels of protection against COVID-19 infections and severe disease in this period when Delta was the dominant strain. Individuals who received the booster dose were less likely by a factor of 11.3 (95% CI: 10.4, 12.3) to develop a confirmed infection and less likely by a factor of 19.5 (95% CI: 12.9, 29.5) to develop severe illness compared to those who were previously fully vaccinated but did not receive a booster dose. The additional protection after receiving a booster translated to vaccine effectiveness comparable to levels seen early in the country’s vaccine rollout (an estimated 95%), when the Alpha variant was predominant.\nUnder the EUA of the Pfizer-BioNTech vaccine in the U.S., a third dose was previously authorized for individuals at least 12 years of age who have undergone solid organ transplant, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. This authorization of a third dose for immunocompromised individuals is separate and distinct from the booster dose reviewed by VRBPAC today. The third dose for immunocompromised individuals is meant to address the fact that these individuals sometimes do not build enough protection after two doses of the vaccine. In contrast, the booster dose recommended today by VRBPAC for EUA refers to an additional dose of the vaccine that is given to those who have built enough protection after the primary two-dose vaccination series, but may have decreased protection over time due to waning of immunity.\nCOMIRNATY, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the United Kingdom, Canada and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries. Submissions to pursue regulatory approvals in those countries where emergency use authorizations or equivalent were initially granted are planned.\nU.S. Indication & Authorized UseCOMIRNATY® (COVID-19 Vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.\n\nIt is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older\nIt is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to:\n\nThe Pfizer-BioNTech COVID-19 Vaccine has received EUA from FDA to:\n\nprevent COVID-19 in individuals 12 years of age and older, and\nprovide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise\n\nThe FDA-approved COMIRNATY® (COVID-19 Vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 Vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 Vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.\nEUA StatementThis emergency use of the product has not been approved or licensed by FDA, but has been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older; and the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.\nImportant Safety InformationIndividuals should not get the Pfizer-BioNTech COVID-19 Vaccine if they:\n\nhad a severe allergic reaction after a previous dose of this vaccine\nhad a severe allergic reaction to any ingredient of this vaccine\n\nIndividuals should tell the vaccination provider about all of their medical conditions, including if they:\n\nhave any allergies\nhave had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)\nhave a fever\nhave a bleeding disorder or are on a blood thinner\nare immunocompromised or are on a medicine that affects the immune system\nare pregnant, plan to become pregnant, or are breastfeeding\nhave received another COVID-19 vaccine\nhave ever fainted in association with an injection\n\nThe vaccine may not protect everyone.\nSide effects reported with the vaccine include:\n\nThere is a remote chance that the vaccine could cause a severe allergic reaction\nMyocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine:\nSide effects that have been reported with the vaccine include:\nThese may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away\n\nThere is no information on the use of the vaccine with other vaccines.\nPatients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.\nPlease click here for full Prescribing Information (16+ years of age). Please click here for Fact Sheet for Vaccination Providers (12+ years of age).\nAbout Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.\nPfizer Disclosure NoticeThe information contained in this release is as of September 17, 2021. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.\nThis release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine, the BNT162 mRNA vaccine program and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose and a supplemental Biologics License Application (sBLA) for a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply) involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; whether and when our Phase 3 clinical trial will demonstrate protection from infection or disease following a booster (third) dose, which is the subject of ongoing study; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial and additional studies or in larger, more diverse populations following commercialization; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the risk that more widespread use of the vaccine will lead to new information about efficacy, safety, or other developments, including the risk of additional adverse reactions, some of which may be serious; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when additional data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications and interpretations; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions and whether and when other biologics license and/or emergency use authorization applications or amendments to any such applications may be filed in particular jurisdictions for BNT162b2 or any other potential vaccines that may arise from the BNT162 program, and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when any applications that may be pending or filed for BNT162b2 (including the sBLA for a potential booster (third) dose in the U.S., applications that may be pending or filed for a potential booster (third) dose in other jurisdictions or any requested amendments to the emergency use or conditional marketing authorizations) or other vaccines that may result from the BNT162 program may be approved by particular regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine’s benefits outweigh its known risks and determination of the vaccine’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners, clinical trial sites or third-party suppliers; the risk that demand for any products may be reduced or no longer exist; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine’s ultra-low temperature formulation, two-dose schedule and attendant storage, distribution and administration requirements, including risks related to storage and handling after delivery by Pfizer; the risk that we may not be able to successfully develop other vaccine formulations, booster doses or new variant-specific vaccines; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand for our vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods as previously indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; challenges related to public vaccine confidence or awareness; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.\nA further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.\nAbout BioNTechBiopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.de.\nBioNTech Forward-looking StatementsThis press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer including the program to develop a COVID-19 vaccine and COMIRNATY (COVID-19 Vaccine, mRNA) (BNT162b2) (including a potential booster (third) dose of BNT162b2 in individuals 16 years of age and older in the U.S., a definite submission of a supplemental BLA for a potential booster dose of a variation of BNT162b2 having a modified mRNA sequence in the U.S., a BLA to support potential full FDA approval of BNT162b2 in individuals 12 through 15 years, whether and when applications for a potential booster (third) dose will be filed in any other jurisdictions, qualitative assessments of available data, potential benefits, expectations for clinical trials, the anticipated timing of regulatory submissions, regulatory approvals or authorizations and anticipated manufacturing, distribution and supply); our expectations regarding the potential characteristics of BNT162b2 in our clinical trials and/or in commercial use based on data observations to date; the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; the expected time point for additional readouts on efficacy data of BNT162b2 in our clinical trials; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; our contemplated shipping and storage plan, including our estimated product shelf life at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and market demand, including our production estimates for 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.\nFor a discussion of these and other risks and uncertainties, see BioNTech’s Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.","news_type":1},"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":143925745,"gmtCreate":1625756854687,"gmtModify":1633937616477,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"likey like tq","listText":"likey like tq","text":"likey like tq","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/143925745","repostId":"1135220115","repostType":4,"isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":898399845,"gmtCreate":1628472161587,"gmtModify":1631889860036,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"likee","listText":"likee","text":"likee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/898399845","repostId":"1136322726","repostType":4,"isVote":1,"tweetType":1,"viewCount":232,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":808620289,"gmtCreate":1627574741841,"gmtModify":1631889860115,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/808620289","repostId":"1131613450","repostType":4,"isVote":1,"tweetType":1,"viewCount":139,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":801367944,"gmtCreate":1627483488988,"gmtModify":1633764549231,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"commenting","listText":"commenting","text":"commenting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/801367944","repostId":"1179923360","repostType":4,"isVote":1,"tweetType":1,"viewCount":261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":172835343,"gmtCreate":1626950110682,"gmtModify":1633769470227,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"weweew","listText":"weweew","text":"weweew","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172835343","repostId":"1137753306","repostType":4,"isVote":1,"tweetType":1,"viewCount":161,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140161977,"gmtCreate":1625638435799,"gmtModify":1633938815354,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"coolsies","listText":"coolsies","text":"coolsies","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/140161977","repostId":"2149365900","repostType":4,"repost":{"id":"2149365900","kind":"highlight","pubTimestamp":1625637675,"share":"https://www.laohu8.com/m/news/2149365900?lang=&edition=full","pubTime":"2021-07-07 14:01","market":"us","language":"en","title":"4 Growth Stocks to Buy in July","url":"https://stock-news.laohu8.com/highlight/detail?id=2149365900","media":"Motley Fool","summary":"Gaming, advertising technology, and emerging markets could be providing investors with some great value.","content":"<p>In today's video I look<b>&nbsp;</b>at fundamentals, valuation metrics, and recent news for <b>Activision&nbsp;</b>(NASDAQ:ATVI), <b>Tencent&nbsp;</b>(OTC:TCEHY), <b>Magnite&nbsp;</b>(NASDAQ:MGNI), and <b>Digital Turbine&nbsp;</b>(NASDAQ:APPS). All four companies are in markets with growth potential and could perform well as long-term investments. Below I share a few highlights from the video.&nbsp;</p>\n<ol>\n <li>A report by App Annie has stated that consumer spending on apps is breaking revenue records in Q2 2021. The four companies in today's video are either in the gaming or the advertising technology industry, both of which could fundamentally benefit from the increase in revenue.&nbsp;</li>\n <li>All four companies have strong financial data for the trailing 12 months. Activision, Tencent, and Digital Turbine all have positive cash flow from operations and positive earnings. Magnite is expected to reach those financial goals within the upcoming 12 months.</li>\n <li>Activision could be giving investors a buying opportunity, as its forward-price-to-sales ratio of 7.4 is currently at levels seen in the summer of 2020.&nbsp;</li>\n</ol>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>4 Growth Stocks to Buy in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n4 Growth Stocks to Buy in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 14:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/06/4-growth-stocks-to-buy-in-july/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In today's video I look at fundamentals, valuation metrics, and recent news for Activision (NASDAQ:ATVI), Tencent (OTC:TCEHY), Magnite (NASDAQ:MGNI), and Digital Turbine (NASDAQ:APPS). All four ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/06/4-growth-stocks-to-buy-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"APPS":"Digital Turbine Inc.","MGNI":"Magnite, Inc.","TCEHY":"腾讯控股ADR","ATV":"橡果国际"},"source_url":"https://www.fool.com/investing/2021/07/06/4-growth-stocks-to-buy-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2149365900","content_text":"In today's video I look at fundamentals, valuation metrics, and recent news for Activision (NASDAQ:ATVI), Tencent (OTC:TCEHY), Magnite (NASDAQ:MGNI), and Digital Turbine (NASDAQ:APPS). All four companies are in markets with growth potential and could perform well as long-term investments. Below I share a few highlights from the video. \n\nA report by App Annie has stated that consumer spending on apps is breaking revenue records in Q2 2021. The four companies in today's video are either in the gaming or the advertising technology industry, both of which could fundamentally benefit from the increase in revenue. \nAll four companies have strong financial data for the trailing 12 months. Activision, Tencent, and Digital Turbine all have positive cash flow from operations and positive earnings. Magnite is expected to reach those financial goals within the upcoming 12 months.\nActivision could be giving investors a buying opportunity, as its forward-price-to-sales ratio of 7.4 is currently at levels seen in the summer of 2020.","news_type":1},"isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804774234,"gmtCreate":1627985070728,"gmtModify":1631889860071,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"wah","listText":"wah","text":"wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804774234","repostId":"2156100119","repostType":4,"repost":{"id":"2156100119","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1627983900,"share":"https://www.laohu8.com/m/news/2156100119?lang=&edition=full","pubTime":"2021-08-03 17:45","market":"us","language":"en","title":"August is among the worst months of year for the stock market. Here's how to play it.","url":"https://stock-news.laohu8.com/highlight/detail?id=2156100119","media":"Dow Jones","summary":"On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulenc","content":"<p>On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.</p>\n<p>The month is associated with the worst performances for the Dow Jones Industrial Average , S&amp;P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.</p>\n<p>The research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.</p>\n<p>To be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.</p>\n<p>However, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&amp;P 500, doesn't mean the long-term trend has changed.</p>\n<p>\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.</p>\n<p>Check out the monthly returns on average since 1950:</p>\n<p>Here are the historical rankings by month via LPL:</p>\n<p>The folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.</p>\n<p>\"Since 1983, the weakest August returns tend to come in years where the S&amp;P 500 was up over 10% YTD heading into the month,\" the researchers note.</p>\n<p>The markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .</p>\n<p><b>So how to play the turbulent stretch?</b></p>\n<p>Jeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.</p>\n<p>\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.</p>\n<p>\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.</p>\n<p>Stock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"</p>\n<p>\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&amp;P 500 sees a push to the 4500-4600 range or even higher.</p>\n<p>Strategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.</p>\n<p>Bespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.</p>\n<p>\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>August is among the worst months of year for the stock market. Here's how to play it.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAugust is among the worst months of year for the stock market. Here's how to play it.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-03 17:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.</p>\n<p>The month is associated with the worst performances for the Dow Jones Industrial Average , S&amp;P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.</p>\n<p>The research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.</p>\n<p>To be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.</p>\n<p>However, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&amp;P 500, doesn't mean the long-term trend has changed.</p>\n<p>\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.</p>\n<p>Check out the monthly returns on average since 1950:</p>\n<p>Here are the historical rankings by month via LPL:</p>\n<p>The folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.</p>\n<p>\"Since 1983, the weakest August returns tend to come in years where the S&amp;P 500 was up over 10% YTD heading into the month,\" the researchers note.</p>\n<p>The markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .</p>\n<p><b>So how to play the turbulent stretch?</b></p>\n<p>Jeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.</p>\n<p>\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.</p>\n<p>\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.</p>\n<p>Stock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"</p>\n<p>\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&amp;P 500 sees a push to the 4500-4600 range or even higher.</p>\n<p>Strategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.</p>\n<p>Bespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.</p>\n<p>\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SSO":"两倍做多标普500ETF","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","UPRO":"三倍做多标普500ETF","IVV":"标普500指数ETF",".SPX":"S&P 500 Index","SH":"标普500反向ETF","OEX":"标普100"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156100119","content_text":"On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.\nThe month is associated with the worst performances for the Dow Jones Industrial Average , S&P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.\nThe research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.\nTo be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.\nHowever, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&P 500, doesn't mean the long-term trend has changed.\n\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.\nCheck out the monthly returns on average since 1950:\nHere are the historical rankings by month via LPL:\nThe folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.\n\"Since 1983, the weakest August returns tend to come in years where the S&P 500 was up over 10% YTD heading into the month,\" the researchers note.\nThe markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .\nSo how to play the turbulent stretch?\nJeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.\n\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.\n\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.\nStock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"\n\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&P 500 sees a push to the 4500-4600 range or even higher.\nStrategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.\nBespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.\n\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.","news_type":1},"isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":804772539,"gmtCreate":1627984888021,"gmtModify":1631889860088,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"wah","listText":"wah","text":"wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/804772539","repostId":"2156100119","repostType":4,"repost":{"id":"2156100119","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1627983900,"share":"https://www.laohu8.com/m/news/2156100119?lang=&edition=full","pubTime":"2021-08-03 17:45","market":"us","language":"en","title":"August is among the worst months of year for the stock market. Here's how to play it.","url":"https://stock-news.laohu8.com/highlight/detail?id=2156100119","media":"Dow Jones","summary":"On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulenc","content":"<p>On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.</p>\n<p>The month is associated with the worst performances for the Dow Jones Industrial Average , S&amp;P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.</p>\n<p>The research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.</p>\n<p>To be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.</p>\n<p>However, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&amp;P 500, doesn't mean the long-term trend has changed.</p>\n<p>\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.</p>\n<p>Check out the monthly returns on average since 1950:</p>\n<p>Here are the historical rankings by month via LPL:</p>\n<p>The folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.</p>\n<p>\"Since 1983, the weakest August returns tend to come in years where the S&amp;P 500 was up over 10% YTD heading into the month,\" the researchers note.</p>\n<p>The markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .</p>\n<p><b>So how to play the turbulent stretch?</b></p>\n<p>Jeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.</p>\n<p>\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.</p>\n<p>\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.</p>\n<p>Stock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"</p>\n<p>\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&amp;P 500 sees a push to the 4500-4600 range or even higher.</p>\n<p>Strategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.</p>\n<p>Bespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.</p>\n<p>\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>August is among the worst months of year for the stock market. Here's how to play it.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAugust is among the worst months of year for the stock market. Here's how to play it.\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-03 17:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.</p>\n<p>The month is associated with the worst performances for the Dow Jones Industrial Average , S&amp;P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.</p>\n<p>The research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.</p>\n<p>To be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.</p>\n<p>However, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&amp;P 500, doesn't mean the long-term trend has changed.</p>\n<p>\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.</p>\n<p>Check out the monthly returns on average since 1950:</p>\n<p>Here are the historical rankings by month via LPL:</p>\n<p>The folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.</p>\n<p>\"Since 1983, the weakest August returns tend to come in years where the S&amp;P 500 was up over 10% YTD heading into the month,\" the researchers note.</p>\n<p>The markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .</p>\n<p><b>So how to play the turbulent stretch?</b></p>\n<p>Jeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.</p>\n<p>\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.</p>\n<p>\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.</p>\n<p>Stock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"</p>\n<p>\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&amp;P 500 sees a push to the 4500-4600 range or even higher.</p>\n<p>Strategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.</p>\n<p>Bespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.</p>\n<p>\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","SSO":"两倍做多标普500ETF","SPXU":"三倍做空标普500ETF","SDS":"两倍做空标普500ETF","OEF":"标普100指数ETF-iShares","UPRO":"三倍做多标普500ETF","IVV":"标普500指数ETF",".SPX":"S&P 500 Index","SH":"标普500反向ETF","OEX":"标普100"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2156100119","content_text":"On Wall Street, August is off to a solid start, but the month tends to accompany a bout of turbulence in equity markets.\nThe month is associated with the worst performances for the Dow Jones Industrial Average , S&P 500 index , as well as the small cap Russell 2000 and large-cap Russell1000 indexes, over the past three decades, according to the folks at Stock Trader's Almanac.\nThe research outfit said that from 1988 to 2020 average declines for the benchmarks ranged from 0.4% for the Russell 2000 to 0.8% by Dow. For the Nasdaq Composite, meanwhile, August ranks as second-worst, with an average gain of 0.2% over the same period, with September being the worst month for the technology-heavy index.\nTo be sure, a year ago, in the midst of the COVID-19 pandemic, August produced stellar returns across the board as investors bet on an eventual rebound in pandemic-plagued markets.\nHowever, last year's uncharacteristically strong performance, which saw monthly gains of over 9% for the Nasdaq Composite and over 7% for the Dow and S&P 500, doesn't mean the long-term trend has changed.\n\"As shown in the LPL Chart of the Day, August and September have been historically two of the weakest months of the year,\" wrote Ryan Detrick, chief market strategist for LPL Financial, in a Monday research note.\nCheck out the monthly returns on average since 1950:\nHere are the historical rankings by month via LPL:\nThe folks at Bespoke Investment Group put a finer point on the underperformance for August, especially after a strong year-to-date performance, as has been enjoyed in 2021.\n\"Since 1983, the weakest August returns tend to come in years where the S&P 500 was up over 10% YTD heading into the month,\" the researchers note.\nThe markets performance thus far has come on the back of stellar earnings results as American corporations rebound from COVID-19, but there are lingering fears that the U.S. has reached or is near peak earnings and economic growth .\nSo how to play the turbulent stretch?\nJeff Hirsch, editor of the Stock Trader's Almanac, said that the first nine trading days of August tend to be the most prone to weakness while the rest of the month is better. That said, he warns that the expirations of futures and options contracts toward the end of the month tend to create a fresh bout of chop in August, heading toward September, another rough patch for stocks.\n\"The end of August tends to be weaker when traders evacuate Wall Street for the summer finale,\" Hirsch wrote.\n\"Expiration week is down more than half the time since 1990, with some sizable losses,\" he said.\nStock Trader's Almanac indicated that bullishness prevails in the market, however. \"Bullish forces continue to persist. The Fed remains easy and accommodative. More fiscal stimulus is likely from Washington as Congress nears finalizing the deals on infrastructure and spending,\" the data company wrote. But it cautioned that outperforming second-quarter earnings and the spread of the Delta variant of COVID-19 \"is a concern and poses a threat to the bull and the economic expansion.\"\n\"Political wrangling here in the States and geopolitical machinations around world could also knock the market off course momentarily,\" Stock Trader's Almanac wrote, while noting that its outlook for the S&P 500 sees a push to the 4500-4600 range or even higher.\nStrategists continue to recommend investment prudence, especially with the benchmark 10-year Treasury yields hanging around a multi-month low near 1.15%.\nBespoke Investment Group also points to a strong 2021, even if the next two months are a bit bumpy, noting that that final stretch of the year tends to be strong when the months leading up to August also have been healthy.\n\"While the average and median returns for August may be lackluster, the final four months of the year have seen an average gain of 5.94% (median: 8.03%) with gains 12 out of 14 times (85%). That's pretty consistent,\" the analysts wrote.","news_type":1},"isVote":1,"tweetType":1,"viewCount":216,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140166026,"gmtCreate":1625638564165,"gmtModify":1633938814399,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"woah woah&nbsp;","listText":"woah woah&nbsp;","text":"woah woah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/140166026","repostId":"1116112587","repostType":4,"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":156711889,"gmtCreate":1625236587441,"gmtModify":1633942192290,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/156711889","repostId":"1196057674","repostType":4,"repost":{"id":"1196057674","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1625229715,"share":"https://www.laohu8.com/m/news/1196057674?lang=&edition=full","pubTime":"2021-07-02 20:41","market":"us","language":"en","title":"5 Warren Buffett Favorites To Keep An Eye On","url":"https://stock-news.laohu8.com/highlight/detail?id=1196057674","media":"Benzinga","summary":"Legendary investor Warren Buffett has posted an impressive 21% year-to-date return for his flagship Berkshire Hathaway Inc  in the first half of 2021.Here's a look at five stocks owned by Buffett and Berkshire Hathaway that could see strong gains in the second half of 2021.Aonreportedfirst-quarter revenue up 10% year-over-year, including organic revenue growth of 6%. The company’s margins improved and earnings per share grew 22% year-over-year. Aon announced a supply chain global protection plan","content":"<p>Legendary investor&nbsp;<b>Warren Buffett</b>&nbsp;has posted an impressive 21% year-to-date return for his flagship&nbsp;<b>Berkshire Hathaway Inc</b>(NYSE:BRKA) (NYSE:BRKB)&nbsp;in the first half of 2021.</p>\n<p>Here's a look at five stocks owned by Buffett and Berkshire Hathaway that could see strong gains in the second half of 2021.</p>\n<p><b>1. Aon:</b>Earlier this year, Berkshire Hathaway took an&nbsp;initial position&nbsp;in insurance broker&nbsp;<b>Aon plc</b>(NYSE:AON). Shares of the company are up 15% year-to-date, could see more upside and could also be a position Buffett adds to.</p>\n<p>Aonreportedfirst-quarter revenue up 10% year-over-year, including organic revenue growth of 6%. The company’s margins improved and earnings per share grew 22% year-over-year. Aon announced a supply chain global protection plan for COVID-19 vaccines that could be a highlight in the next earnings report.</p>\n<p><b>2. Apple:</b>There have been several rallies for technology stocks in the first half of 2021. Despite the rallies, shares of technology giant&nbsp;<b>Apple Inc</b>(NASDAQ:AAPL) traded flat in the first half of 2021.</p>\n<p>Apple makes up the largest stock holding in the Berkshire Hathaway portfolio. The iPhone maker&nbsp;continues to be an innovator and should not be overlooked for more product launches and announcements in the second half of the year that could move shares of the stock higher.</p>\n<p><b>3. Bank of America:</b>&nbsp;<b>Bank of America Corporation</b>(NYSE:BAC) is a large holding of Buffett's and one of several bank stocks that he has kept. Buffett has significantly lowered the company’s weighting in&nbsp;<b>Wells Fargo Co</b>(NYSE:WFC), a stock it once owned 10% of and started investing in dating back to 1989.</p>\n<p>Bank of America could be Buffett's favored banking stock and it comes as the company reported record consumer investment assets and record client balances in thefirst quarter.</p>\n<p>Revenue for the first quarter of $22.8 billion was flat year-over-year but several areas saw strong demand and growth. The company announced it's raising its quarterly dividend from 18 cents to 21 cents in late June and could continue to raise dividends after passing a new bank stress test.</p>\n<p><b>4. Coca-Cola:</b>One of Buffett's favorites&nbsp;is<b>&nbsp;Coca-Cola Co</b>&nbsp;(NYSE:KO). Shares of the beverage giant are down 1% in the first half of 2021 as many consumer food and beverage companies have seen positive returns. The company could be due to make a bigacquisitionlike that of&nbsp;<b>Monster Beverage Corporation</b>(NASDAQ:MNST) orpushing furtherinto alcoholic beverages.</p>\n<p><b>5. Verizon:</b>Shares of&nbsp;<b>Verizon Communications</b>(NYSE:VZ) are down around 4% in the first half of 2021. The companyreportedtotal revenue of $32.9 billion in the first quarter, up 4% year-over-year. Several of the company’s core business segments saw single-digit growth.</p>\n<p>A shift to 5G nationwide could help a company like Verizon, which along with a near 5% dividend yield could make the communications giant a stock to watch in the second half of 2021.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Warren Buffett Favorites To Keep An Eye On</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Warren Buffett Favorites To Keep An Eye On\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-07-02 20:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Legendary investor&nbsp;<b>Warren Buffett</b>&nbsp;has posted an impressive 21% year-to-date return for his flagship&nbsp;<b>Berkshire Hathaway Inc</b>(NYSE:BRKA) (NYSE:BRKB)&nbsp;in the first half of 2021.</p>\n<p>Here's a look at five stocks owned by Buffett and Berkshire Hathaway that could see strong gains in the second half of 2021.</p>\n<p><b>1. Aon:</b>Earlier this year, Berkshire Hathaway took an&nbsp;initial position&nbsp;in insurance broker&nbsp;<b>Aon plc</b>(NYSE:AON). Shares of the company are up 15% year-to-date, could see more upside and could also be a position Buffett adds to.</p>\n<p>Aonreportedfirst-quarter revenue up 10% year-over-year, including organic revenue growth of 6%. The company’s margins improved and earnings per share grew 22% year-over-year. Aon announced a supply chain global protection plan for COVID-19 vaccines that could be a highlight in the next earnings report.</p>\n<p><b>2. Apple:</b>There have been several rallies for technology stocks in the first half of 2021. Despite the rallies, shares of technology giant&nbsp;<b>Apple Inc</b>(NASDAQ:AAPL) traded flat in the first half of 2021.</p>\n<p>Apple makes up the largest stock holding in the Berkshire Hathaway portfolio. The iPhone maker&nbsp;continues to be an innovator and should not be overlooked for more product launches and announcements in the second half of the year that could move shares of the stock higher.</p>\n<p><b>3. Bank of America:</b>&nbsp;<b>Bank of America Corporation</b>(NYSE:BAC) is a large holding of Buffett's and one of several bank stocks that he has kept. Buffett has significantly lowered the company’s weighting in&nbsp;<b>Wells Fargo Co</b>(NYSE:WFC), a stock it once owned 10% of and started investing in dating back to 1989.</p>\n<p>Bank of America could be Buffett's favored banking stock and it comes as the company reported record consumer investment assets and record client balances in thefirst quarter.</p>\n<p>Revenue for the first quarter of $22.8 billion was flat year-over-year but several areas saw strong demand and growth. The company announced it's raising its quarterly dividend from 18 cents to 21 cents in late June and could continue to raise dividends after passing a new bank stress test.</p>\n<p><b>4. Coca-Cola:</b>One of Buffett's favorites&nbsp;is<b>&nbsp;Coca-Cola Co</b>&nbsp;(NYSE:KO). Shares of the beverage giant are down 1% in the first half of 2021 as many consumer food and beverage companies have seen positive returns. The company could be due to make a bigacquisitionlike that of&nbsp;<b>Monster Beverage Corporation</b>(NASDAQ:MNST) orpushing furtherinto alcoholic beverages.</p>\n<p><b>5. Verizon:</b>Shares of&nbsp;<b>Verizon Communications</b>(NYSE:VZ) are down around 4% in the first half of 2021. The companyreportedtotal revenue of $32.9 billion in the first quarter, up 4% year-over-year. Several of the company’s core business segments saw single-digit growth.</p>\n<p>A shift to 5G nationwide could help a company like Verizon, which along with a near 5% dividend yield could make the communications giant a stock to watch in the second half of 2021.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BAC":"美国银行","BRK.A":"伯克希尔","AAPL":"苹果","WFC":"富国银行","BRK.B":"伯克希尔B","AON":"怡安保险","KO":"可口可乐","MNST":"怪物饮料"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196057674","content_text":"Legendary investor Warren Buffett has posted an impressive 21% year-to-date return for his flagship Berkshire Hathaway Inc(NYSE:BRKA) (NYSE:BRKB) in the first half of 2021.\nHere's a look at five stocks owned by Buffett and Berkshire Hathaway that could see strong gains in the second half of 2021.\n1. Aon:Earlier this year, Berkshire Hathaway took an initial position in insurance broker Aon plc(NYSE:AON). Shares of the company are up 15% year-to-date, could see more upside and could also be a position Buffett adds to.\nAonreportedfirst-quarter revenue up 10% year-over-year, including organic revenue growth of 6%. The company’s margins improved and earnings per share grew 22% year-over-year. Aon announced a supply chain global protection plan for COVID-19 vaccines that could be a highlight in the next earnings report.\n2. Apple:There have been several rallies for technology stocks in the first half of 2021. Despite the rallies, shares of technology giant Apple Inc(NASDAQ:AAPL) traded flat in the first half of 2021.\nApple makes up the largest stock holding in the Berkshire Hathaway portfolio. The iPhone maker continues to be an innovator and should not be overlooked for more product launches and announcements in the second half of the year that could move shares of the stock higher.\n3. Bank of America: Bank of America Corporation(NYSE:BAC) is a large holding of Buffett's and one of several bank stocks that he has kept. Buffett has significantly lowered the company’s weighting in Wells Fargo Co(NYSE:WFC), a stock it once owned 10% of and started investing in dating back to 1989.\nBank of America could be Buffett's favored banking stock and it comes as the company reported record consumer investment assets and record client balances in thefirst quarter.\nRevenue for the first quarter of $22.8 billion was flat year-over-year but several areas saw strong demand and growth. The company announced it's raising its quarterly dividend from 18 cents to 21 cents in late June and could continue to raise dividends after passing a new bank stress test.\n4. Coca-Cola:One of Buffett's favorites is Coca-Cola Co (NYSE:KO). Shares of the beverage giant are down 1% in the first half of 2021 as many consumer food and beverage companies have seen positive returns. The company could be due to make a bigacquisitionlike that of Monster Beverage Corporation(NASDAQ:MNST) orpushing furtherinto alcoholic beverages.\n5. Verizon:Shares of Verizon Communications(NYSE:VZ) are down around 4% in the first half of 2021. The companyreportedtotal revenue of $32.9 billion in the first quarter, up 4% year-over-year. Several of the company’s core business segments saw single-digit growth.\nA shift to 5G nationwide could help a company like Verizon, which along with a near 5% dividend yield could make the communications giant a stock to watch in the second half of 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":128,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":834592172,"gmtCreate":1629812270596,"gmtModify":1631889859995,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"whee","listText":"whee","text":"whee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/834592172","repostId":"1154386229","repostType":4,"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":831136474,"gmtCreate":1629294304098,"gmtModify":1631889860035,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"wa","listText":"wa","text":"wa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/831136474","repostId":"2160735178","repostType":4,"repost":{"id":"2160735178","kind":"highlight","pubTimestamp":1629292500,"share":"https://www.laohu8.com/m/news/2160735178?lang=&edition=full","pubTime":"2021-08-18 21:15","market":"us","language":"en","title":"3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over Fist","url":"https://stock-news.laohu8.com/highlight/detail?id=2160735178","media":"Motley Fool","summary":"Berkshire Hathaway's stakes in these top-tier companies were reduced during the second quarter.","content":"<p>When it comes to investing prowess, Warren Buffett is in a class of his own. Since taking the helm of conglomerate <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in 1965, he's helped deliver an average annual return to shareholders of 20%. That's 56 years and an <i>average annual return of 20% </i>over those 56 years! Taking into account the year-to-date gain from the Class A shares (BRK.A), Buffett has overseen a nearly 3,400,000% return in Berkshire Hathaway's stock while CEO.</p>\n<p>Suffice it to say, when Warren Buffett buys, adds to, reduces, or sells out of a stock, Wall Street and the investing community pay very close attention. On Monday, Aug. 16, investors received their latest peek under the hood.</p>\n<p><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</p>\n<h3>Berkshire Hathaway was a net-seller of stocks in Q2</h3>\n<p>Companies and individuals managing at least $100 million in assets are required to file Form 13F with the Securities and Exchange Commission 45 days after a quarter has ended. A 13F provides a (dated) snapshot of what institutional investors, hedge funds, or market mavens were holding as of the end of the most recent quarter (June 30).</p>\n<p>Berkshire Hathaway's latest 13F showed a considerable amount of selling, rather than buying. In total, four stocks were purchased or added to during the second quarter, with the biggest buy being grocery chain <b>Kroger</b>. More than 10.7 million shares were added, boosting Berkshire Hathaway's stake to almost 61.8 million shares.</p>\n<p>On the other hand, 11 stocks were reduced or completely given the heave-ho. <b>Axalta Coating Systems</b>, Berkshire Hathaway's only exposure to the materials sector, was completely sold. Additionally, the Oracle of Omaha and his investing team sent <b>Biogen</b>&nbsp;and <b><a href=\"https://laohu8.com/S/LFG.AU\">Liberty</a> Global </b>(Class A, LBTYA) packing. Note, Berkshire still owns a reduced stake in <b>Liberty Global</b>'s Class C shares (LBTYK).</p>\n<p>But among the eight other holdings that were reduced are three stocks that investors should be buying hand over fist. Buffett and his investing lieutenants may have an impressive track record, but they're not infallible.</p>\n<p><img src=\"https://static.tigerbbs.com/fe7d1b8c040ec63440ca65517ac114c2\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>The all-electric 2022 Chevrolet Bolt EUV. Image source: General Motors.</p>\n<h3>General Motors</h3>\n<p>First up is auto stock <b>General Motors</b> (NYSE:GM), which has been consistently trimmed in recent quarters. During the second quarter, Buffett and his team reduced Berkshire's GM stake by 7 million shares, leaving the company with 60 million shares.</p>\n<p>Why reduce the General Motors stake? One possibility is persistent supply chain disruption caused by the coronavirus pandemic. Chip shortages have caused automakers to halt or reduce production of certain models, which should adversely affect their operating performance in the near term.</p>\n<p>Another possible reason Buffett or his investing lieutenants, Todd Combs and Ted Weschler, may have chosen to lighten the load is GM's valuation. Since emerging from bankruptcy over a decade ago, GM's market cap was never higher than it was during the second quarter (a peak of $92 billion).</p>\n<p>But whatever the reasoning is, selling shares of General Motors isn't a smart move. If anything, General Motors is more attractive now than it's been in over a decade. That's because it's going to benefit from a multi-decade vehicle replacement cycle as consumers and enterprises go electric.</p>\n<p>In mid-June, General Motors announced its plans to up spending on electric vehicles (EV), autonomous vehicles, and battery technology to $35 billion through 2025. That's a 75% increase from its previous spending commitment on clean-energy solutions from prior to the pandemic. The expectation is that GM will launch 30 new EVs worldwide by mid-decade.</p>\n<p>General Motors also has significant inroads in China, the world's largest auto market. With a number of established brands in the Chinese market and the infrastructure necessary to ramp up production, GM shouldn't have any issue gobbling up EV market share.</p>\n<p>Currently valued at less than 8 times Wall Street's earnings-per-share forecast for 2022, GM is a screaming buy.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F639553%2Fusb-mobile-app.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: U.S. Bank (U.S. Bancorp is U.S. Bank's parent company).</p>\n<h3>U.S. Bancorp</h3>\n<p>Another surefire winner that was, once again, reduced very modestly by Buffett and his team during the quarter is regional bank stock <b>U.S. Bancorp</b> (NYSE:USB). In total, 798,178 shares were sold, equating to a 0.6% reduction from its first-quarter stake. All told, Berkshire Hathaway still holds almost 128.9 million shares of U.S. Bancorp.</p>\n<p>If you're looking for a valid reason why 798,178 shares were sold during the second quarter, the best guess I can offer is Berkshire Hathaway wanting to keep away from the 10% ownership threshold for banks that would qualify it as a bank holding company (BHC). As a BHC, Berkshire's reporting and trading activity would be considerably more stringent than it is now. Perhaps Buffett was anticipating Berkshire's stake in U.S. Bancorp growing due to future buybacks.</p>\n<p>But like GM, it really doesn't matter why Buffett sold. Right now, U.S. Bancorp is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the most attractive bank stocks investors can buy.</p>\n<p>To start with, it's consistently near the top or leading big banks in return on assets (ROA). Whereas most banks strive for a 1% ROA, U.S. Bancorp has a knack for delivering a 1.6% ROA, which is indicative of its fantastic management team. This is a company that's stuck true to the bread-and-butter of banking (i.e., loan and deposit growth), and has generally avoided the riskier derivative investment opportunities that ravaged money-center banks during the Great Recession.</p>\n<p>Furthermore, U.S. Bancorp is a banking leader when it comes to digital adoption. Approximately 79% of its customers were active digitally (online or mobile) in the May-ended quarter, which is up 7 percentage points from the comparable quarter two years prior. What's more, nearly two-thirds of all loan sales were completed online or via mobile app since 2021 began.</p>\n<p>As one of the nation's most efficient banks, U.S. Bancorp is set to thrive as the U.S. economic recovery takes shape.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F639553%2Fbiotech-lab-research-with-multiple-pipettes-getty.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Bristol Myers Squibb</h3>\n<p>A third stock Berkshire Hathaway reduced in the second quarter is pharmaceutical giant <b>Bristol Myers Squibb</b> (NYSE:BMY). A little over 4.7 million shares were sold, which ultimately reduced Buffett's company's stake by 15% to roughly 26.3 million shares.</p>\n<p>Before diving into the \"why?\" part of the selling process, it's important to note that this position is almost certainly the responsibility of Buffett's investing lieutenants. The Oracle of Omaha has never had the interest or energy to keep up with clinical trials, which is a big reason he's generally avoided drugmakers over the years.</p>\n<p>As for why the Bristol Myers position was cut by 15%, there are two possible explanations. First, the company has stalled out around $70 a share on two previous occasions (1999 and 2016). With the company pushing back into the mid-$60 range in the second quarter, perhaps Combs and Weschler felt it was a prudent time to lock in some gains.</p>\n<p>The second possibility is that Bristol Myers Squibb was purchased as a coronavirus play, and it simply hasn't materialized as one.</p>\n<p>Not to sound like a broken record, but whatever the reasoning is, selling Bristol Myers Squibb at less than 9 times forward-year earnings is a mistake. This is a healthcare stock investors should be buying hand over fist.</p>\n<p>On the organic growth front, Bristol Myers is making waves. Eliquis, which was developed in combination with <b>Pfizer</b>, has become the leading oral anticoagulant and is on track for more than $10 billion in annual sales. Meanwhile, cancer immunotherapy Opdivo brought in $7 billion last year and is being examined in dozens of clinical trials as a monotherapy or combination treatment. Label expansion opportunities offer ample upside for Opdivo.</p>\n<p>Bristol Myers Squibb also turned heads with its 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene brought one of the world's top-selling cancer drugs, Revlimid, into the fold. Revlimid's annual sales have grown by a double-digit percentage for more than a decade, with the multiple myeloma drug benefiting from improved cancer-screening diagnostics, strong pricing power, increased duration of use, and label expansions. Since it's protected from a flood of generic competition until February 2026, Bristol Myers has a long runway to reap the rewards of its new cash cow.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over Fist</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over Fist\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-18 21:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/18/3-stocks-buffett-is-selling-you-should-be-buying/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When it comes to investing prowess, Warren Buffett is in a class of his own. Since taking the helm of conglomerate Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965, he's helped deliver an average ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/18/3-stocks-buffett-is-selling-you-should-be-buying/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GM":"通用汽车","BRK.A":"伯克希尔","USB":"美国合众银行","BRK.B":"伯克希尔B"},"source_url":"https://www.fool.com/investing/2021/08/18/3-stocks-buffett-is-selling-you-should-be-buying/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2160735178","content_text":"When it comes to investing prowess, Warren Buffett is in a class of his own. Since taking the helm of conglomerate Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in 1965, he's helped deliver an average annual return to shareholders of 20%. That's 56 years and an average annual return of 20% over those 56 years! Taking into account the year-to-date gain from the Class A shares (BRK.A), Buffett has overseen a nearly 3,400,000% return in Berkshire Hathaway's stock while CEO.\nSuffice it to say, when Warren Buffett buys, adds to, reduces, or sells out of a stock, Wall Street and the investing community pay very close attention. On Monday, Aug. 16, investors received their latest peek under the hood.\n\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nBerkshire Hathaway was a net-seller of stocks in Q2\nCompanies and individuals managing at least $100 million in assets are required to file Form 13F with the Securities and Exchange Commission 45 days after a quarter has ended. A 13F provides a (dated) snapshot of what institutional investors, hedge funds, or market mavens were holding as of the end of the most recent quarter (June 30).\nBerkshire Hathaway's latest 13F showed a considerable amount of selling, rather than buying. In total, four stocks were purchased or added to during the second quarter, with the biggest buy being grocery chain Kroger. More than 10.7 million shares were added, boosting Berkshire Hathaway's stake to almost 61.8 million shares.\nOn the other hand, 11 stocks were reduced or completely given the heave-ho. Axalta Coating Systems, Berkshire Hathaway's only exposure to the materials sector, was completely sold. Additionally, the Oracle of Omaha and his investing team sent Biogen and Liberty Global (Class A, LBTYA) packing. Note, Berkshire still owns a reduced stake in Liberty Global's Class C shares (LBTYK).\nBut among the eight other holdings that were reduced are three stocks that investors should be buying hand over fist. Buffett and his investing lieutenants may have an impressive track record, but they're not infallible.\n\nThe all-electric 2022 Chevrolet Bolt EUV. Image source: General Motors.\nGeneral Motors\nFirst up is auto stock General Motors (NYSE:GM), which has been consistently trimmed in recent quarters. During the second quarter, Buffett and his team reduced Berkshire's GM stake by 7 million shares, leaving the company with 60 million shares.\nWhy reduce the General Motors stake? One possibility is persistent supply chain disruption caused by the coronavirus pandemic. Chip shortages have caused automakers to halt or reduce production of certain models, which should adversely affect their operating performance in the near term.\nAnother possible reason Buffett or his investing lieutenants, Todd Combs and Ted Weschler, may have chosen to lighten the load is GM's valuation. Since emerging from bankruptcy over a decade ago, GM's market cap was never higher than it was during the second quarter (a peak of $92 billion).\nBut whatever the reasoning is, selling shares of General Motors isn't a smart move. If anything, General Motors is more attractive now than it's been in over a decade. That's because it's going to benefit from a multi-decade vehicle replacement cycle as consumers and enterprises go electric.\nIn mid-June, General Motors announced its plans to up spending on electric vehicles (EV), autonomous vehicles, and battery technology to $35 billion through 2025. That's a 75% increase from its previous spending commitment on clean-energy solutions from prior to the pandemic. The expectation is that GM will launch 30 new EVs worldwide by mid-decade.\nGeneral Motors also has significant inroads in China, the world's largest auto market. With a number of established brands in the Chinese market and the infrastructure necessary to ramp up production, GM shouldn't have any issue gobbling up EV market share.\nCurrently valued at less than 8 times Wall Street's earnings-per-share forecast for 2022, GM is a screaming buy.\n\nImage source: U.S. Bank (U.S. Bancorp is U.S. Bank's parent company).\nU.S. Bancorp\nAnother surefire winner that was, once again, reduced very modestly by Buffett and his team during the quarter is regional bank stock U.S. Bancorp (NYSE:USB). In total, 798,178 shares were sold, equating to a 0.6% reduction from its first-quarter stake. All told, Berkshire Hathaway still holds almost 128.9 million shares of U.S. Bancorp.\nIf you're looking for a valid reason why 798,178 shares were sold during the second quarter, the best guess I can offer is Berkshire Hathaway wanting to keep away from the 10% ownership threshold for banks that would qualify it as a bank holding company (BHC). As a BHC, Berkshire's reporting and trading activity would be considerably more stringent than it is now. Perhaps Buffett was anticipating Berkshire's stake in U.S. Bancorp growing due to future buybacks.\nBut like GM, it really doesn't matter why Buffett sold. Right now, U.S. Bancorp is one of the most attractive bank stocks investors can buy.\nTo start with, it's consistently near the top or leading big banks in return on assets (ROA). Whereas most banks strive for a 1% ROA, U.S. Bancorp has a knack for delivering a 1.6% ROA, which is indicative of its fantastic management team. This is a company that's stuck true to the bread-and-butter of banking (i.e., loan and deposit growth), and has generally avoided the riskier derivative investment opportunities that ravaged money-center banks during the Great Recession.\nFurthermore, U.S. Bancorp is a banking leader when it comes to digital adoption. Approximately 79% of its customers were active digitally (online or mobile) in the May-ended quarter, which is up 7 percentage points from the comparable quarter two years prior. What's more, nearly two-thirds of all loan sales were completed online or via mobile app since 2021 began.\nAs one of the nation's most efficient banks, U.S. Bancorp is set to thrive as the U.S. economic recovery takes shape.\n\nImage source: Getty Images.\nBristol Myers Squibb\nA third stock Berkshire Hathaway reduced in the second quarter is pharmaceutical giant Bristol Myers Squibb (NYSE:BMY). A little over 4.7 million shares were sold, which ultimately reduced Buffett's company's stake by 15% to roughly 26.3 million shares.\nBefore diving into the \"why?\" part of the selling process, it's important to note that this position is almost certainly the responsibility of Buffett's investing lieutenants. The Oracle of Omaha has never had the interest or energy to keep up with clinical trials, which is a big reason he's generally avoided drugmakers over the years.\nAs for why the Bristol Myers position was cut by 15%, there are two possible explanations. First, the company has stalled out around $70 a share on two previous occasions (1999 and 2016). With the company pushing back into the mid-$60 range in the second quarter, perhaps Combs and Weschler felt it was a prudent time to lock in some gains.\nThe second possibility is that Bristol Myers Squibb was purchased as a coronavirus play, and it simply hasn't materialized as one.\nNot to sound like a broken record, but whatever the reasoning is, selling Bristol Myers Squibb at less than 9 times forward-year earnings is a mistake. This is a healthcare stock investors should be buying hand over fist.\nOn the organic growth front, Bristol Myers is making waves. Eliquis, which was developed in combination with Pfizer, has become the leading oral anticoagulant and is on track for more than $10 billion in annual sales. Meanwhile, cancer immunotherapy Opdivo brought in $7 billion last year and is being examined in dozens of clinical trials as a monotherapy or combination treatment. Label expansion opportunities offer ample upside for Opdivo.\nBristol Myers Squibb also turned heads with its 2019 acquisition of cancer and immunology drugmaker Celgene. Buying Celgene brought one of the world's top-selling cancer drugs, Revlimid, into the fold. Revlimid's annual sales have grown by a double-digit percentage for more than a decade, with the multiple myeloma drug benefiting from improved cancer-screening diagnostics, strong pricing power, increased duration of use, and label expansions. Since it's protected from a flood of generic competition until February 2026, Bristol Myers has a long runway to reap the rewards of its new cash cow.","news_type":1},"isVote":1,"tweetType":1,"viewCount":322,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":892488985,"gmtCreate":1628683856647,"gmtModify":1631889860025,"author":{"id":"3577522329316309","authorId":"3577522329316309","name":"pompeepee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577522329316309","idStr":"3577522329316309"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/892488985","repostId":"2158186289","repostType":4,"isVote":1,"tweetType":1,"viewCount":195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}